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ABSTRACT 
 
 
CRISTINA BACIU. Bioinformatics and biomolecular tools for biomarker discovery in 
peripheral blood lymphocytes from patients with Sporadic Amyotrophic Lateral 
Sclerosis. (Under the direction of DR. JENNIFER W. WELLER) 
 
Sporadic Amyotrophic lateral sclerosis (sALS) is a complex, invariably fatal, disease 
with a poorly understood cause, despite many studies. Diagnostic biomarkers that 
precede active symptoms would be an immense help to clinicians, for patient 
management, following the progress of clinical studies, and uncovering early events in 
the development and progression of the disease.  
Combining bioinformatics of microarrays and molecular biology assays we analyzed 
and extended the results from experiments performed on peripheral blood lymphocyte 
(PBL) fractions from an sALS and a normal-matched coronary artery disease (CAD) 
study. We developed a novel computational pipeline (LO-BaFL) to improve the power 
and discrimination of identifying differentially expressed (DE) genes on long-
oligonucleotide arrays. From sALS samples we performed quantitative polymerase chain 
reaction (qPCR) validation assays that linked three novel genes, ACTG1, B2M, and 
ILKAP, to sALS. Selected regions of the DE transcripts were sequenced, which revealed 
a new, albeit non ALS-linked mutation. Genes revealed as DE by LO-BaFL were 
examined through pathway and network interaction analysis. Heightened profiles are 
seen in the immune response signature, apoptosis and responses to chemical stimulus; 
these correspond well to phenotypes associated with sALS and are good candidates for a 
simplified blood-based biomarker signature. 
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CHAPTER 1: THE LO-BaFL PIPELINE FOR MICROARRAY EXPRESSION 
ANALYSIS 
 
 
1.1 Introduction  
Biomolecular component: Biology and biomarker discovery in ALS 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is one the 
most well known of the motor neuron diseases, being described for the first time in 1869 
[1]. It is characterized by the progressive degeneration of upper (in the brain) and lower 
(in spinal cord) motor neurons that in turn alters the muscle normal functions, causing 
muscle weakness and atrophy that ultimately leads to death, within 1.5-5 year following 
diagnosis [1-3]. ALS usually affects people in their 50s, with an incidence of 1-3 cases in 
100,000/year. About 5 to 10 % of cases are familial ALS (fALS), caused mainly by 
autosomal dominant genetic mutations, the remaining 90 to 95% being sporadic (sALS), 
with an etiology still to be determined [1, 4, 5]. 
Extensive research in the pathogenesis of fALS has been stimulated by the discovery 
of mutations in Cu/Zn superoxide dismutase 1 (SOD1) that are responsible for 
approximately 20% of fALS cases. This fact is substantiated by the demonstration that 
SOD1 mutations in mouse models reproduce a motor neuron disease phenotype [6, 7]. 
Recent studies have shown that mutations in two additional genes are associated with
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premature degeneration of the motor neurons in both forms of ALS: the TARDBP at the 
ALS10 locus on chromosome 1, and the FUS/TLS gene at the ALS6 locus on 
chromosome 16 [2, 8-13]. Mutations in these genes determine, however, independent 
neurodegeneration events in patients with amyotrophic lateral sclerosis, as FUS/TLS 
mutations are not present in fALS patients with SOD1 or TARDBP mutations and vice 
versa [2].  
In recent years, the development of high-throughput and targeted sequencing and 
sequence interrogation methods has increased, at a very large scale, the number of 
available human genome sequences for molecular analysis. Several whole-genome 
association studies (WGAS) have been conducted in order to discover single nucleotide 
polymorphisms, SNPs, conferring susceptibility to sALS [13-15]. While in some studies 
weak associations were found, there were no overlapping results and two of the studies 
could not find any significant association of SNPs with ALS [14, 15]. The other studies 
associated independent, distinct SNPs with sALS, corresponding to the FLJ10986, ITPR2 
and DPP6 genes, respectively [16-18]. Only the association with DPP6 has been 
successfully replicated (in an Italian population) as shown in one study, but not in a 
second pool of samples (from Poland) [19, 20]. In addition, two studies that determined 
copy number variants (CNVs) associated with sALS in geographically different 
populations have been conducted. Again, correlated mutations were not replicated 
between studies [21, 22]. Therefore, either very large studies or different targets will be 
needed in order to clearly demonstrate the link between specific loci and sALS.  
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There are several proposed mechanisms associated with motor neuron degeneration in 
ALS: oxidative stress, toxicity induced by mutant SOD1 through different cellular 
processes, formation of intracellular aggregates (which are sometimes observed), 
mitochondrial abnormalities, deficiency in axonal transport, apoptosis, and others [1, 23, 
24]. Many of these processes are found in sALS, but are also common to 
neurodegenerative diseases in general such as Alzheimer’s, Parkinson’s, Fronto-
Temporal Dementia or prion diseases.  
Many biological and genetic studies have been conducted on biofluids or biopsies 
from sALS patients, but these studies have not yet led to the identification of a common 
aberrant process. RiluzoleTM, a drug that inhibits glutamate uptake by CNS neurons, is 
the only approved FDA drug for ALS treatment. It extends the life of ALS patients by 
only 2-3 months, on average. When ALS is diagnosed earlier, treatment with Riluzole is 
generally more effective. Therefore, early diagnosis biomarkers such as differentially 
expressed genes that can be measured by assays performed on drawn blood are sought for 
quality of life issues alone, although a cure is obviously the eventual goal. It is hoped that 
early biomarkers may provide new insights into causal agents or pathways involved in 
degenerative mechanisms that can be potentially exploited for drug target discovery. 
Early detection might help us capture the mechanisms of initiation and early progression 
in which processes are reversible, or holding patients in pre-symptomatic stages as some 
of the multiple sclerosis treatments appear to do [25]. Even without understanding the 
causal event, markers of disease progression are needed to study responses to new drugs 
and facilitate clinical trials.  
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Bioinformatics component 
Oligonucleotide microarrays are extensively used for genomics studies (particularly 
transcriptomics and genotyping). The platforms were the first fully parallel instruments 
for assessing cell state, and remain powerful tools for pursuing biological mechanisms in 
the context of their full complexity, i.e., covariation in gene expression levels, detection 
of both alleles and haploblocks for SNPs and CNVs in genotyping, etc.[26-29]. However, 
despite their wide-spread use and frequent success, the correct handling of the 
measurements is still subject to debate, and conflicting interpretations are common [26]. 
Many factors contribute to the controversy. An individual’s divergence from the 
‘reference standard’ used in platform design is one factor [5, 6, 7], whose impact will 
become clearer as more genomes and variants are described [30]. Biophysical properties 
of the sensors are also important factors [27, 28]. Alternate transcript forms are a variable 
for eukaryotic genomes [29]; probes are unlikely to report on all variants. Noise has both 
biological and technical sources, including factors such as availability of a homogeneous 
sample and the completeness of amplification and fragmentation steps [31]. The effect of 
these factors on measurements is amenable to description and modeling: doing so 
improves the processing of the data [26].  
In developing the data cleansing pipeline presented here, we considered those factors 
that can be identified with respect to a reference genome and databases of common 
variants, as well as biophysical factors for the most prevalent of the long-oligonucleotide 
arrays used to produce public datasets, the Agilent human 4x44k platform. The pipeline 
logically resembles the BaFL pipeline that was developed for short oligonucleotide 
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probes [32], but differs in the particulars because the Agilent platform uses longer probes 
(60-mers) and has less intentional redundancy, with 1-2 probes per gene compared to 
Affymetrix arrays 11-16 probes (25-mers) per gene. Accommodating these differences 
requires modifying parameters in the algorithms and tests used to identify and map 
probes to the genome, since the length of a duplex affects it’s stability under given 
hybridization conditions. For example, SNPs affect a measurement when they lie in the 
probe-target duplex, but the number required to eliminate the signal is correlated to the 
length of the duplex [33-35]. Similarly, internal probe or target structures compete with 
duplex, usually lowering the signal [36-38]; G runs (> 3) are a well-known special case 
[14-16]. Confirming the target requires remapping the probe to its genomic context, 
outcomes of which include identifying: (i) cross-hybridization to additional distant 
genomic locations; (ii) loss of binding site, where no stable complement exists; (iii) mis-
location, requiring reassignment of the probe to a new gene (re-annotation); (iv) 
confirming correct, unique matches to the intended target. Where a sequence-based 
problem is identified a probe’s measurement should be removed from all samples – this is 
most simply handled by altering the file describing the array layout e.g. with Aroma [39-
41]. 
Not all error comes from sequence bias, sample handling and scanners also 
contribute. The instrument has important response characteristics to consider [42, 43], 
and the upper and lower limits of signal detection must be adjusted by experiment and 
platform. Variance from sample handling steps is examined after problematic probes 
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have been removed: the pipeline incorporates several statistical tests to determine sample 
membership in the designated classes [32].  
For rare, sporadic diseases such as ALS, it is difficult to obtain large sample sizes, 
therefore for statistical rigor and to make sure that a consistent effect is identified, meta-
experiments are needed. The challenge is to identify samples that can legitimately be 
grouped and then to process the data in such a way that responses are similarly scaled. 
Only high quality sample annotation can ensure the first criterion, while removing probes 
known to have flaws and observing scanner response limitations helps with the second. 
Since all DE predictions require a robust normal control, and the sample size in our 
original study was very small [44], we obtained the CAD study [45] for its normal 
samples, whose age, gender and cell mixture characteristics were well-matched to our 
samples, as an independent control of the quality of our ALS normal cohort. 
The effectiveness of a data processing pipeline is generally assessed by the accuracy 
of subsequent data mining efforts, which at the lowest level are tests for differential 
expression across states [46]. The most accepted confirmatory tests are sample-based, 
using an independent assay method (usually qRT-PCR), but may be meta-analysis based 
when samples are unavailable, using literature reports to reinforce the analysis findings. 
After processing data with both a standard pipeline, TM4 [47], and our LO-BaFL 
pipeline, we used SAM [24] to generate the DE predictions upon which effective 
processing is judged. Since a small amount of the ALS material amplified for the 
microarrays was available, some predictions were tested by qRT-PCR assays. To provide 
meta-analysis support, and because the ALS sample numbers were so small, the CAD 
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normal sample analysis was added. We note that in the original CAD study qRT-PCR 
was used to test some of the predictions, and we have assumed that the reported results 
were accurate.  Microarray and qRT-PCR results were declared concordant when the 
direction and the degree of change in expression compared to a control gene were 
accurately captured [48]. Finally, we performed a literature search for independent 
reports on a number of the genes, or pathway and interaction data predicted and 
confirmed to be important in these ALS samples [49].   
We mention above that a ‘standard’ pipeline is used as well as the one we developed. 
As an open source for microarray data analysis, TM4 [47] consists of a series of 
applications under a graphical interface that facilitates analyses of microarray data. 
Among the TM4 suite of tools, MIDAS (Microarray Data Analysis System) includes 
several normalization steps (e.g., total intensity normalization, Lowess normalization, 
standard deviation regularization), and filtering to remove low intensity signals. There are 
several options for statistical analysis on filtered data to determine differentially 
expressed genes, i.e. parametric versus non-parametric tests. The TM4 pipeline uses 
statistical rather than biophysical criteria to remove poor measurements [47, 50] and it 
does not explicitly list the deprecated probes, so understanding directly what response 
changes have lead to different outcomes is not possible. To test whether the LO-BaFL 
processing pipeline has advantages over TM4 when array studies using small sample 
sizes are involved, we used each pipeline to process two independent data sets. We then 
used a significance test for DE genes, applying a simple Wilcoxon non-parametric test 
because the distributions did not meet criteria to use a parametric test [28]. For the ALS 
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samples, we performed the qRT-PCR assays on the unused portion of the products sent 
for array hybridization [51] while for the subset of samples from the CAD experiment we 
relied on the published qRT-PCR results and literature references.  
1.2 Materials and methods 
For data storage, data organization, and recording the order and parameters used in 
the pipeline transformations, we have used DataFATE (Data - Feature Analysis 
Transformation Extraction), a software system based on a relational model that includes a 
toolset with data import and organization tools for relational database management 
systems (RDBMS), tools for factor (quantitation type, QT) definition, QT set 
construction, and storage of data from processing steps. The RDBMS is currently 
PostgreSQL 8.0.3. [52]. The project instance of DataFATE was installed into a 64 bit, 22-
processor, 120 GB of RAM computer running Ubuntu 9.04 version for Kernel LINUX™ 
2.6.28, as the operating system. Querying, extraction and manipulation of data stored in 
DataFATE has been made with scripts written with Python 2.6 [53], SQL (via 
PGAdminIII) [54] and R [55]. Additional software installed on this hardware and used 
for this project includes TM4 microarray software suite [56], and OligoArrayAux [29] for 
biophysical modeling. For the results using the packages TM4 [47] and Significance 
Analysis of Microarrays (SAM) [57], we set up the relational database in order to 
maintain stable output of intermediate and final results of both pipelines.  
Data acquisition 
Microarray image files and corresponding spot intensity values for the ALS study were 
provided by Carolinas Neuromuscular/ALS-MDA Center, Neuroscience and Spine 
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Institute, Carolinas Medical Center, Charlotte, NC. The microarray experiment used 
Agilent 4x44K human genome microarrays [58] in a pooled reference design [59]. 
Sample and microarray processing were performed at Cogenics [60], producing arrays 
contrasting each sample (healthy and diseased) to the healthy reference pool. The raw 
data sent back by Cogenics includes extracted spot intensities and the background-
subtracted intensity ratios for each contrast.  
CAD raw data was downloaded from GEO, Accession No.GSE10195. 
The LO-BaFL pipeline  
The steps in the pipeline, described below, are summarized in Figure 1.1.   
A. In this section the probe-sequence based filters are described. 
(i) Re-map the Agilent probes to assembly version 36.1 of the human genome (36.1) 
using the accelerated Tera-BLAST algorithm, as implemented by a TimeLogic-Decypher 
[61] server. The corresponding matches were deposited into an instance of the DataFATE 
database. Parameters were: nucleic match = 1; nucleic mismatch = -3; open penalty = -5; 
extend penalty = -2; threshold significance = 10. The input and output files can be found 
in Supplementary Material section, at: http://webpages.uncc.edu/~cbaciu/LO-
BaFL/supplementary_data.html under Input Files/agilent_fasta or Cleansing 
Process/tera_blast_results.  
(ii) Determine the cross-hybridization potential of probes to other sites in the genome, 
using the Kane criteria [62]. Briefly this is an empirical rule stating that any target 
sequence with similarity greater than 75% across the length of a probe can contribute a 
detectable amount of signal to the total intensity. 
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Figure 1.1 Flowchart of the LO-BaFL pipeline: the pipeline step is given on the left and 
the right indicates where intermediate datasets were stored in the project database. Note 
that this output has been made available as flat files. 
 
This rule includes some constraints concerning the positions and lengths of mismatch 
regions. For a probe to cross-hybridize, we input the following conditions: percent 
identity ≥ 85%; presence of 50 matches out of 60 possible; minimum of 15 consecutive 
nucleotides in the Agilent probe sequence. We stored the output, consisting of all the 
Kane-criteria cross-hybridizing probes into DataFATE.  
(iii) Identify probes that no longer anchor to the reference genome. This information 
is acquired when a TeraProbe query returns ‘no hit’, and this is stored as an explicit type.   
(iv) Identify SNPs and short indels known to occur in the probe-binding region. 
Probes were mapped to the human instance of dbSNP [63], taking all possible alternate 
Re-map the Agilent probes to 
HuRef 36.1 (Tera-BLAST) Perfect Matches
Determine the probes that cross-
hybridize (Kane criteria) Cross-hyb probes
Identify the probes with known 
SNPs (map to dbSNP)
Probes with 4 
SNPs or more
Identify the probes with low 
binding affinity (OligoArrayAux)
Probes forming  too stable 
and unstable structures
Statistical analyses
DataFATE
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alleles into consideration. The minimum number of SNPs expected to significantly 
degrade the signal is a parameter in the BaFL pipeline. Using the Kane criteria, the 
presence of six SNPs will reduce the signal to the point of background, but the presence 
of any SNP will cause the signal to reflect both sequence variation and transcript 
concentration and the question of degree is not simple since it depends on sequence 
context and competition.  For the case study we set the ‘deprecate’ flag to 3 SNPs or 
more, assuming that this many competing alleles would make the intensity information 
useless for differential expression analysis. All of the information was retained, however, 
so another researcher could modify the query to adjust the number of SNPs to allow in 
retrieved probes.  
(v) Employ the OligoArrayAux software [29] to determine the free energy of internal 
probe structures versus heterodimers. Parameters chosen were: temperature 55 to 62º C, 
concentrations of 1.0 M Na+ and 0.0 M Mg++, output was used to define probes 
inaccessible to target (except at very high concentrations) under experimental conditions. 
Probes that predominantly form very stable internal structures have a lower effective 
concentration, and so bind less target. Heterodimers with low stability under specific 
experimental conditions do not yield signal [64-66]. The predicted value of the most 
stable form is stored in the database as an attribute of the probe, allowing adjustment of 
the cut-off value.  
(vi) It has been shown for Affymetrix arrays that four or more consecutive guanines 
(G-runs) lead to unusual probe structures that cause very high signal [14-16]. We 
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identified the probes with this feature; we note that most of them are removed based on 
other filters as well (data not shown). 
(vii) The presence of any member of the transposable elements family, short (SINE), 
long (LINE) or primate-specific (Alu) repeat elements, can have a great affect on gene 
expression [45-47]. Using the TranspoGene database[67] we examined the entire set of 
genes for these elements; none were identified. 
Note that the order of operations is independent for the above filters; some probes fall 
into multiple categories so the total number of ‘bad’ probes identified per step will be 
greater than the total number removed.  
B. Background (Noise Estimation) 
The probes that form very stable heterodimers and have a single target (do not cross-
hybridize) can provide insight into expected noise from the Agilent scanner (it must be 
estimated since the information is not given). Once this value has been determined, it can 
be used as a filter for eliminating the probes that have signal below the detection 
boundary. Candidate probes were identified using queries for uniqueness and free energy; 
measurement values were then retrieved, from each dataset independently, and the mean, 
median and lowess values were determined.  
  C. Sample Outlier Detection 
We compared the signal intensities in the normal and diseased samples to the mean 
and variance of each class, and the distributions in order to identify samples outliers. Two 
contrasts were examined: 
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(i) Sample to class comparison of average number or probes and intensity per probe: 
Using only probes with acceptable measurement-yielding profiles, for each sample class 
and accepting only measurements above the lower detection boundary, we determined the 
mean signal per probe per array and across all arrays in the class. Samples whose probe-
signal mean fell more than two standard deviations outside of the array mean were 
rejected. We then determined the number of acceptable probes that yielded good 
measurements per array, and across all arrays in the class, and similarly rejected any 
sample for which the number of informative probes fell more than two standard 
deviations from the class mean.  
(ii) Sample distribution comparisons using filtered probe intensities: We compared 
the within- category and between-category distributions of probe intensities in the 
measurement-quality class. Non-normal distributions would suggest application of a log 
transformation, while sufficiently dissimilar distributions (test is described below) 
preclude the use of some statistical tests.   
Statistical Analyses for Distribution 
For the arrays that passed the LO-BaFL pipeline, the distributions of the intensities of 
the final set of acceptable probe values were tested for each class and experiment. 
Individual normal and diseased samples were labeled with Cy3 and the pooled reference 
was labeled with Cy5, which means the pooled reference group had twice as many 
members. The Shapiro-Wilk test [68-70], implemented in R, was used to check for 
normal distribution within and between sample classes. Since the results of both 
experiments show a non-normal distribution (data not shown), the Wilcoxon non-
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parametric test[71],[72] for unpaired groups was applied when performing comparisons 
for differential expression.  
Significance of Differential Expression 
Microarrays are the poster child for the multiple-hypothesis testing conundrum [73]. 
We addressed this issue using the Benjamini and Hochberg FDR procedure [74] 
implemented in R. The output consists of a list of DE genes and associated p-values. The 
R scripts for statistical analysis and the output file with DE genes can be found in 
Supplementary Material / Scripts/ stats_R.txt. 
The control method, TM4 [47, 56] takes as input the spot intensity values for a set of 
arrays categorized by experimental design. TM4 allows for signal normalization (total 
intensity normalization, Lowess normalization), standardization (standard deviation 
regularization) and low-signal intensity filtering. Modified intensity values are the output, 
which are then used by the Significance Analysis of Microarray (SAM) package [57] or 
non-parametric tests to identify the differentially expressed genes. The output is a list of 
DE genes and associated p-values. The sequences of steps performed as statistical 
analyses are shown in Figure 1.2. 
1.3 Results and Discussions 
The pipeline for probe filtering 
Data: the raw microarray data is publicly available at NCBI Gene Expression 
Omnibus, GSE28253 [75].  The specified intermediate pipeline output and the final 
results of our analyses are available in the Supplementary Material section unless noted. 
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Is the sample an 
outlier in its class?
Is the distribution of 
the 2 sample sets 
very different?
Apply Welch t-test, FDR 
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TM4 DE genes
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Candidate genes
for qRT-PCR
1
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Original Array Design
(no probe  filtering)
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tests
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Apply SAM
SAM DE genes
3
LO-BaFL DE genes
 
Figure 1.2 The LO-BaFL pipeline (1) and the TM4 (2) and SAM (3) pipelines. 
Pipeline: 
 (i) Re-mapping the Agilent probes to the Human Reference (HuRef) Genome 36.1 
build. The 41,000 Agilent probes were scanned against the human reference genome 
using the Tera-BLAST algorithm implemented on the FPGA-accelerated platform from 
TimeLogic [61]. This search was implemented to find near-perfect as well as perfect 
matches, using parameter settings mentioned in the Materials and Methods section. We 
found a total of 370,139 hits to the probes, averaging ~9 matches per probe. The full list 
16 
 
of matches is available on the project Web site / Cleansing 
process/tera_blast_results/tera_blast_raw.zip. In a gene expression array the impact of a 
perfect match to a secondary target depends on whether it is an expressed sequence from 
the complementary strand. The majority of additional locations did map to genes and did 
not appear to map across exon/intron junctions, although this does depend on the gene 
model used (data not shown).  
(ii) Perfect and partial matches. Where a secondary target is not a perfect match there 
must be some boundary conditions for determining where sufficient signal contamination 
will occur to confound the interpretation of the data. We chose to follow the Kane criteria 
[62], adapted to Agilent 60-mers, such that 50/60 nucleotides have to match overall, with 
a minimum nucleation length of 15 nucleotides somewhere in the duplex. Applying these 
filters to the output above suggests that ~8.63 % of the probes would produce confounded 
measurements (signal coming from distinct loci), and that subset of probes was flagged. 
Oligonucleotides that report on multiple loci are usually eliminated from the 
measurement pool, at least in initial data cleansing efforts, since interpretation of the 
values is problematic [76, 77]. The file so modified is provided on the project Web site 
under Cleansing Process/cross-hybridization_filter/total_probes_no_crosshyb.csv. 
(iii) Identifying the loss of probes. There are 407 probes that no longer map to the 
HuRef Genome 36.1 build (file = probes_info_no_pm_no_crosshyb_not_mapped.csv in 
Supplementary Data/Cleansing Process / loss_of_target_filter), these were flagged for 
removal from the active probes list.  
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(iv) Identifying the presence of SNPs. Although the cut-off is somewhat arbitrary, 
probes with four or more SNPs were removed (~2.53% of the remainder), since their 
presence would significantly distort the apparent concentration [65, 66]. The file showing 
the probes and the major/minor alleles for each SNP position is in Supplementary 
Material/Cleansing process/SNP filter/snp_info_probes_gt_4snp.csv. A separate file, 
’agilent_probe_info_3SNPs.csv’ gives the information on probes with less than four 
SNPs, for those wishing to adjust the stringency of SNP cut-offs.  
(v) Delta G filter. The logic for deciding the cut-off for internal stability is described 
in the original BaFL report. For these 60-mers and hybridization conditions, ∆G = -5.2 
kcal mol-1 shows the comparable response [32], resulting in filtering out ~21.5 % of the 
probes, listed in the Supplementary Material file under “DeltaG_filter” tables.  
The summary of the pipeline effects (as percent of probes filtered out per step) is 
shown in Table 1.1. 
(vi) Poly-G filter. A factor added to the BaFL pipeline subsequent to the published 
report is the presence of poly-G (a run of G’s >3) in the probe (Thompson, personal 
communication). The phenomenon of ‘bright spots’ from such runs has only been 
reported for short oligo arrays [14-16], but it is reasonable to check for them on longer 
oligonucleotide arrays as well. There are 4,742 such probes in the original data set (see 
file ‘log_signal_4G_probes_total_no_filters.csv,’ under polyG_filter of Cleansing 
Process in Supplementary Material). Of these ~10.2% had unusually high intensity 
(log10(I) > 3.5) while 50% had log10(I) < 2.0. Only 11 probes with this feature were 
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present in the final list of acceptable probes (explained below), and these were flagged 
for removal. 
Table 1.1. The % probes removed in total by applying the filtering steps of LO-
BaFL pipeline and comparison with percent probes eliminated in the original 
BaFL pipeline.   
 
 
Applied filter 
% Probes filtered 
out (LO-BaFL) 
% Probes filtered 
out (BaFL) [32] 
Cross-hybridization 8.63 % 60.30% 
Loss of target 0.99 % 2.19 % 
SNP  2.53 % 1.78% 
∆G  21.46 % 5.17% 
 
 
 
 
 
 
 (vii) Repeated elements filter. A screen of the remaining probes for LINE, SINE and 
Alu subsequences was performed against the TranspoGene database [67]; no matches 
were identified. 
Background estimation (instrument cut-off value) 
The lower detection limit for our Agilent scanner was not available as a technical 
specification, so it was necessary to estimate it. Since this is not a standard method in 
most analysis pipelines the rationale for the steps is given here. Probes that do not cross-
hybridize are used, in order to limit the possibility that a high concentration of target 
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comes from an unexpected source. From these we selected those with a very stable 
internal structure so that little was available for duplex formation with target (∆G < -5.2 
kcal mol-1); this subset is given in (Supplementary Data/Cleansing 
process/Determining_instrument_cutoff/delta_g_mean_and_log_int_probes_no_crosshyb
.csv). The goal is to identify a cutoff below which there is little variation in signal across 
many different probes, indicating that the response to changes target concentration has 
been compressed. In examining the intensities of this subset of probes in both normal and 
diseased samples in the ALS study, log10(I)mean and log10(I)median yielded values of 3.51 
and 3.49 respectively, while for the CAD samples the values were 3.0 and 2.9 
respectively, which indicates that this is either an experiment- or a scanner-specific value 
(we cannot separate labeling and scanner sensitivity factors). This is ten-fold higher than 
the value we find for most experiments using Affymetrix scanners (Thompson, personal 
report). If the extremely stable probes are eliminated (∆G < -10 kcal mol-1), the 
background cut-off values approach the Lowess smoothing values, shown in Figure 1.3 
for the ALS samples (lower panel), and also in Figure S1 for the CAD data (see 
‘Supplementary Data/CAD study’), and now approximate the values (200-300 
fluorescent units) seen for the Affymetrix scanners. In the absence of calibration 
standards we cannot discriminate scanner detection limits from target fragmentation and 
labeling efficiency, but clearly the noise limit is experiment dependent and should be 
carefully determined for each experiment, and standardized for meta-experiments. This 
filter caused the largest single-step removal of probes for ALS experiment with all 
samples (~27,000 probes = ~ 95% of the total removed in this step, Supplementary 
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Material/Cleansing Process / Instrument_cutoff / all_samples_gt_instrument_cut-
off_log_intens.csv). If a smaller value (2.5) for instrument cut-off is used, the percent of 
probes removed by this filter is reduced to ~ 78%, but the list of DE genes obtained is not 
any more similar to TM4 than before (see Results). 
Sample outlier identification 
We mirrored the BaFL approach for detecting sample outliers: briefly, one determines 
for each sample in a class the number of probes whose signal is above background and 
the the average signal per probe and compares the values to the sample-class means [32]. 
In experiments conducted on human patients with long-standing debilitating disease there 
is a strong likelihood that multiple conditions are present; a large difference in the 
number and identity of genes expressed may mean that part of the response is due to a 
second agent, so samples are screened for large overall response differences. A second 
difference from the earlier pipeline arose because of the experimental design of one these 
studies: the ALS experiment used a common reference design, so we added a step to 
determine how reproducible the signal of that reference is across all of the samples. Any 
sample (here represented by the array) for which the number of probes or intensity per 
probe falls more than two standard deviations from the mean for the category is 
considered an outlier and is not used. Defining an outlier as more than two standard 
deviations away from the class mean for either of these criteria, none of the samples in 
the ALS experiment failed, including those that were not tested by gene-specific PCR 
because of poor RIN numbers, indicating that the original samples were most likely of 
acceptable quality. No sample outliers were detected in the CAD experiment.  
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Figure 1.3. (upper) Graphical representation of ∆Gcut-off  results: the probes having free 
energy, ∆G < -5.2 kcal mol-1, represented by the red line, were filtered out and the 
proportion to the left of the line is 21.5%; (lower) ∆G vs. Probe signal: the red line 
denotes background cut-off value; grey line is the Lowess smoothing line between ∆G 
and log10 intensities; grey dots represent the probes with very stable structures that have 
been eliminated in the process; black dots represent the probes with signal higher than the 
background cut-off value and ∆G < -5.2 kcal mol-1.  
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Additional Probe Restrictions 
In the set of 12 samples whose cDNA passed the quality control (QC) step (see 
below), a set of 1,552 common probes was retained by the filtering process. Including the 
12 samples with somewhat degraded cRNA (poor RIN scores) decreases the number to 
1,327 probes to test for expression differences.   
Sample Distribution Testing and Predicting Differential Expression 
 Once unreliable sensors (flawed probes) and measurements (scanner limitations) have 
been screened out, comparisons of the remaining intensity distributions allow one to 
select a valid statistical method to identify differentially expressed targets. In both 
studies, the F test indicated unequal variances between the two groups of samples. Probes 
for the same gene in the two sample classes failed the Shapiro-Wilks test for normality 
[68-70]. Our results indicated the presence of unequal and non-normal distributions (see 
Figure 1.4 and Figures S2, S3 in Supplementary Data/CAD Study); therefore, the use of a 
nonparametric equivalent to the t-test was chosen: in this case, the Wilcoxon two-sample 
test for unpaired groups [71, 72] was applied. The multiple-comparison problem is well-
known for these experiments; we controlled for the false discovery rate (FDR) [74] using 
a setting of 0.20 and corrected the p-values accordingly with either the Bonferroni 
correction [78] or the Benjamini and Hockberg correction [74]. In each case no DE genes 
remained, suggesting that the criteria were too stringent. If we accept the argument that 
the multiple-testing criteria are too stringent [79], and use a p < 0.05 for significance, in 
the ALS experiment 87 probes were returned as DE for the complete dataset, with a 
subset of 60 of those reported as DE in the high-quality samples.  
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 For the CAD study, 386 genes were found to be differentially expressed. The list with 
all DE genes for ALS is provided for each set, in Supplementary Material/Data post 
filtering/DE_genes_12(or all)_samples tables. DE genes for the CAD experiment are 
listed in: 
 Supplementary Data / CAD Study / DE_genes_CAD / DE_genes_CAD_data.csv.  
TM4 and Significance Analysis of Microarrays (SAM) for ALS Data set  
 TM4, a widely-accepted platform for analyzing Agilent microarray data, incorporates 
SAM, which included a choice of non-parametric tests for the statistical analysis; thus we 
selected it as the standard pipeline against which to compare the LO-BaFL pipeline. 
Using the ALS experiment samples, analyses using several parameter settings were 
performed so that we could compare outcomes, and we used both the complete sample 
set and the highest RIN quality-validated subset of samples for each. The base-line 
analysis used TM4 default settings, which includes several normalization steps (e.g., total 
intensity normalization, Lowess normalization, standard deviation regularization), and 
filtering for the lowest 5% intensity signals, a common signal detection boundary of 100 
for Cy5 and Cy3 intensities, and the Wilcoxon non-parametric test to determine DE genes 
(for convenience we label the results of using this method ‘TM4-W’). A second analysis 
path used LO-BaFL to remove problematic probes and the Wilcoxon non-parametric t-
test to determine DE genes. It is possible that the data cleansing results are essentially the 
same even if the approach is not, so we used the LO-BaFl results as input to SAM, and 
within SAM opted for the Wilcoxon test (labelled as ‘SAM-W’). 
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   Figure 1.4. Q-Q plot distribution of diseased (upper) and healthy controls (lower). 
The main caveat in this comparison is that there must be a sufficient number of 
observations in the classes for the method to be valid. SAM takes measurements and 
response variable category as input, and uses permutations to determine the strength of 
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association; we set the permutation number to 100. Table 1.2 compares the six lists of 5 
most significantly DE genes obtained from our analyses. The R implementation and 
SAM implementation of the Wilcoxon are very similar, with SAM perhaps being slightly 
more stringent since it eliminates one gene allowed by the other algorithm. The number 
of samples made a large difference, with only 1 of 5 genes being in common when 12 or 
22 samples were processed with LO-BaFL (that being JUNB) or with TM4 (the gene 
being DYNLT1). An obvious reason for the disparity is if the probes have been 
deprecated in the list of acceptable probes. Checking the list of such probes showed that 
four of the TM4 DE genes fell below the minimum signal boundary set for LO-BaFL, 
explaining their absence. The fifth TM4-predicted gene, DYNLT1 did not appear on the 
LO-BaFL list because it did not meet the p-value criterion.  
Confirmatory analyses on DE genes in CAD samples 
The list of DE genes determined by LO-BaFL was compared with results reported in 
[45]. Two of the genes appear on both lists (CSPG2, ALOX5), four are close variants of 
the DE genes, while the remainder of the genes reported in the paper were eliminated 
from out list based on specific criteria including the strong structure (delta G), low signal 
(scanner limitation) or p-values that failed our significance criterion (See ‘Supplementary 
Material / CAD study / comparison_with_DE_genes_CAD  / comparison_LO-
BaFL_CAD_DE_genes.csv’). The file listing DE genes for this experiment as determined 
by our pipeline is found as ‘LO-BaFL_DE_genes_CAD_data.csv’, located in the same 
directory mentioned above.   
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Analysis of Healthy Control samples from a different experiment and comparison 
with Healthy Controls from ALS data. 
A major shortcoming of many analysis pipelines is that they are over-tuned to a 
particular experiment, so that parameters that yield excellent results in one study give 
poor results in another.Our intent is that the LO-BaFL filters be mostly experiment-blind 
(except for the determination of scanner detection limit and sample outlier status); if this 
is true LO-BaFL should predict the behavior of genes in similar samples but different 
experiments relatively well.  
We looked for experiments in which human peripheral-blood samples and the Agilent 
arrays were used. One such studied coronary artery disease (CAD) [45] from controls 
(n=14) and diseased (n = 27). The data is accessible at GEO, Accession No.GSE10195. 
We compared the behavior of the two control groups: those without CAD in one study 
(six randomly selected samples out of 14) and without ALS in the other (six controls). An 
anomaly in the CAD study was a number of spots with ‘negative’ intensities (often 
saturated spots that the software does not know how to handle), which were removed. 
Prior to probe filtering, all of the samples have measurements for 24,336 genes. After 
LO-BaFL filtering being applied we graphed and compared the probe intensities in 
Normal samples from each study. We found a good correlation across genes between the 
two groups, indicated by the near-linearity of the Lowess smoothing line, shown in red 
(Figure 1.5). The genes that are most highly expressed in each set of samples (e.g. RPS2, 
RPLP1, RPS28, HLA-C) and expressed at low but detectable levels (e.g. CD28, CDV3, 
CD79A, CCD12) are characteristic of white blood cells.  
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Table 1.2 ALS experiment: Selected differentially expressed genes with p < 0.05, 
determined by LO-BaFL-Wilcoxon (LO/W12, LO/W22), TM4-W (TM4/W12, 
TM4/W22) and SAM-W (SAM/W12, SAM/W22). 
 
List of DE 
genes 
Gene/Accession Description p-value /q-value 
LO/W12 FTH1/ NM_002032 Ferritin, heavy polypeptide 1 1.59E-3 
 JUNB/ NM_002229 Jun B proto-oncogene 3.67 E-3 
 B2M/ NM_004048 Beta-2-microglobulin 1.54 E-3 
 ACTG1/ NM_001614 Poly(A) binding protein, cytoplasmic 1 3.7 E-3 
 SLC25A3/NM_005888 
solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 3 
4.46 E-3 
LO/W22 EXOC3L2/NM_138568 Exocyst complex component 3-like 2 5.73 E-3 
 FAU/ NM_001997 
Finkel-Biskis-Reilly murine sarcoma 
virus 
1.96 E-3 
 GLTSCR1/ AF182077 
Glioma tumor suppressor candidate 
region gene 1 
2.56 E-3 
 JUNB/ NM_002229 Jun B proto-oncogene 1.24 E-3 
 IRS2/ NM_003749 Insulin receptor substrate 2 1.66 E-3 
TM4/W12 CSE1L/ NM_001316 
CSE1 chromosome segregation 1-like 
(yeast) 
0.0 
 NUP88/ NM_002532 Nucleoporin 88kDa 0.0 
 PARP1/NM_001618 poly (ADP-ribose) polymerase 1 0.0 
 DYNC1I2/NM_001378 
Dynein, cytoplasmic 1, intermediate 
chain 2 
0.0 
 DYNLT1/ NM_006519 Dynein, light chain, Tctex-type 1 0.0 
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Table 1.2 (continued) 
 
TM4/W22 TARDBP/NM_007375 TAR DNA binding protein 0.0 
 DYNLT1/ NM_006519 Dynein, light chain, Tctex-type 1 0.0 
 SKIV2L2/ NM_015360 
Superkiller viralicidic activity 2-like 2 
(S. cerevisiae)  
0.0 
 C12orf35/NM_018169 Chromosome 12 open reading frame 35  0.0 
 IRS2, NM_003749 Insulin receptor substrate 2  0.0 
SAM/W12 FTH1/ NM_002032 Ferritin, heavy polypeptide 1 0.0 
 JUNB/ NM_002229 Jun B proto-oncogene 0.0 
 B2M/ NM_004048 Beta-2-microglobulin 0.0 
 ACTG1/ NM_001614 Poly(A) binding protein, cytoplasmic 1 0.0 
 SLC25A3/NM_005888 
solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 3 
0.0 
SAM/W22 IRS2/ NM_003749 Insulin receptor substrate 2 0.0 
 GLTSCR1/ AF182077 
Glioma tumor suppressor candidate 
region gene 1 
0.0 
 FAU/ NM_001997 
Finkel-Biskis-Reilly murine sarcoma 
virus 
0.0 
 EXOC3L2/NM_138568 Exocyst complex component 3-like 2 0.0 
 JUNB/ NM_002229 Jun B proto-oncogene 0.0 
 
This result encourages us that we can extend our studies to additional microarray data 
of ALS samples, since LO-BaFL predictions of DE genes are often confirmed by qRT-
PCR results. 
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1.4 Conclusions 
We performed two related case studies, using data obtained from independent 
experiments, one on ALS and one on CAD. Transcript levels for both experiments were 
measured with the Agilent 4x44k platform. The data was processed using two pipelines: 
LO-BaFL and TM4.  
 
Figure 1.5. Correlation between healthy controls in ALS and CAD studies denoted by the 
Lowess smoothing line in red.  
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Comparing normal samples from the independent CAD experiment [47] to the ALS-
normal samples indicated that the latter microarray hybridizations gave very similar 
results (albeit with somewhat different labeling efficiency), giving us more confidence in 
the differences observed with the diseased samples for the quite small ALS study. Several 
of the most significant DE genes in ALS were related to immune responses, while in the 
CAD study the DE genes were involved in atherosclerosis, cell motility, as signaling 
receptors or transcription factors [45]. Our pipeline was applied to the CAD data as a 
whole (healthy n = 14, diseased n = 27), paying particular attention to those DE genes 
that the researchers of the original study tested with qRT-PCR assays. We compared the 
DE genes determined by LO-BaFL with their list and the result shows that except for 
several genes that have been eliminated by ∆G filter or by the background cut-off filter, 
the rest are found in our list with significant expressed genes. Two of them are confirmed 
to be DE, four are close variants and several others were dropped because the p-value fell 
just below our cut-off (See Supplementary Material/CAD study). Furthermore, a 
comparative analysis of controls in ALS study vs. controls in CAD study shows a very 
good correlation between the two groups. 
We note that these studies had considerably fewer disease samples than were 
available for the original BaFL study, which used a large, publicly available lung cancer 
dataset. ALS is sporadic, rare, and has a mysterious etiology [1, 7, 13]; the inherent small 
number of samples means that methods for increasing the power of studies are even more 
important. 
 
 
 
 
 
CHAPTER 2: VALIDATION OF DIFFERENTIALLY EXPRESSED GENES 
ASSOCIATED WITH sALS BY qRT-PCR ASSAYS 
 
 
2.1 Introduction 
The research described in this chapter represents an extensive investigation of the 
differentially expressed genes, as determined by applying LO-BaFL pipeline, defined in 
details in Chapter 1, to available microarray data and by comparative bioinformatics 
methods, e.g. TM4, in peripheral blood lymphocytes (PBLs) from patients with sALS, 
and normal patients, samples provided by Carolinas Neuromuscular/ALS-MDA Center, 
Charlotte, NC.  
Employing different methods to obtain DE genes on same the data set has the 
advantage of determining a more complete list. More specifically, the LO-BaFL pipeline 
is designed to eliminate and flag any probes that are cross-hybridizing, whereas TM4 and 
SAM do not have this filter. For instance, one Agilent probe representing TARDBP, one 
of the most important genes in sALS studies, was found to cross-hybridize with IlKAP. 
The latter was not identified by TM4 as being differentially expressed and therefore, it 
would have been excluded for further assays if only the TM$-SAM computational 
method was used.  Because LO-BAFL identifies genes by category, cross-hybridizing 
genes can be specifically identified in the absence of microarray DE predictions. Thus we 
added to the list of genes to test by qPCR TARDBP and ILKAP, neither of which was 
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predicted as significantly DE by LO-BAFL and only the first of which was predicted by 
TM4.  
For any diagnostic test a confirmation of the results must be demonstrated using an 
independent method. This is particularly true of microarray results, which tend to produce 
long lists of DE genes that appear only in single studies. While the follow-up assay id not 
prescribed, it is most commonly a quantitative PCR assay, either absolute or relative, 
since the set of collective methods is sensitive and reproducible. Because reagents for the 
absolute quantitation method do not exist for the amplicons in our study we chose the 
relative quantitative approach. This requires that the different efficiencies of 
amplification be considered in the data analysis, explained in more detail in the 
Discussion section.  
2.2 Materials and Methods 
Gene selection 
We selected FTH1, JUNB, B2M, ACTG1, SLC25A3 as top common DE genes for 
LO-W and SAM-W (see Chapter 1), and in addition, SKIV2L2, C12orf35, DYNLT1 and 
TARDBP (determined by TM4-W) and its corresponding cross-hybridizing genes (e.g. 
ILKAP, DIAPH3), to be tested in the lab.  
Also, we adopted a set of four reference genes to assess the sample and assay 
conditions, according to best practice recommendations [49]. A reference is context 
specific: these were selected based on an apparently consistent level of expression in the 
microarray data across sample classes and individuals, in the middle range of 
concentrations. These references included: UBE2Z (ubiquitin-conjugating enzyme E2Z), 
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PGK1 (phosphoglycerate kinase 1), COX4I1 (cytochrome c oxidase subunit IV isoform 
1), and SRRM1 (serine/arginine repetitive matrix 1).  
The qRT-PCR assay reagents and quantitation templates were developed and the 
titrations of samples against standards performed according to standard methods [51]. 
Primers and reference template sequences are provided in Table 2.1. The instrument was 
the Bio-RAD MyiQ Single-Color Real-Time PCR Detection System [80]. We used the 
software that ships with the instrument to perform initial calculations; we chose the 
maximum correlation coefficient approach to determine the Cts, from which the starting 
concentrations of the unknowns were estimated. Further analyses were performed with 
the Pfaffl method [81].  
In the absence of a calibration standard the actual expression levels of genes in the 
individual samples are not readily available. Thus the wet-lab work had two goals: 
determine the level of expression that a microarray value yields in a qRT-PCR assay; 
determine whether either pipeline was accurate in its predictions of the predicted 
difference in expression levels between normal and diseased samples. Table 2.1 shows 
the genes selected and their category. Those marked as ‘reference’ are expected to be 
expressed in PBLs at moderate and consistent levels in all samples.  
 A diagram representing the four steps involved the experimental part of the present 
study is sketched in Figure 2.1. 
Quantitative and qualitative assessment of RNA  
The isolated RNA from peripheral blood lymphocytes samples of healthy controls 
and ALS patients, stored at -80º C, provided by Carolinas Neuromuscular/ALS-MDA 
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Center, Chalotte, NC was qualitatively checked using the Agilent 2100 Bioanalyzer [58], 
and quantified with the Nanodrop ND-1000 from ThermoScientific [82]. We carried 
forward only those samples that satisfied the condition that RIN >5.5.  
cDNA synthesis and QC 
In addition to the samples used in the microarray experiments, we extracted RNA from 
other samples of blood cells, suspended in Trizol and kept at -80º C, as positive controls, 
using the AllPrep DNA/RNA Mini Kit from Qiagen [83], following the manufacturer’s 
instructions. This RNA was qualified and quantified as above. We then synthesized 
double-stranded cDNA from the ALS samples that passed the RNA quality/quantity test 
(6 normal controls and 6 diseased) and from the control RNA, using the Full SpectrumTM 
Complete Transcriptome RNA Amplification Kit from System Biosciences [84], 
according to the supplier’s manual. After quantification of the yield, and standardization 
of the concentrations, the cDNA products were qualified by determining whether the 
reference gene PCR primers yielded the expected size product on 12% acrylamide 
(native, in 1X TBE buffer) gels [85]. Even where the starting concentration of RNA was 
low, e.g; 20 ng, we obtained good yields of cDNA. The PCR reaction conditions were as 
follows, per 50ul final volume: 5.0 µl /reaction of 10X Buffer (InvitrogenTM [86]), 3.5 µl 
/reaction MgCl2 (InvitrogenTM [86], 50 mM stock solution, for Mg++ 3.5 mM final 
concentration), 2.5 µl /reaction dNTP mixture (InvitrogenTM [86], 10 mM stock, 2.5 mM 
final ), 0.5 µl /reaction DNA Taq Polymerase (BioLabs® Inc.[87] concentration of 100 
mM stock; final concentration of 5 mM), 2.0 µl /reaction cDNA as template (100 ng). 
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Table 2.1 The list of reference genes and DE genes as determined by qRT-PCR and their 
corresponding designed primers. 
Gene information Gene role 
Forward primer (5` to 3`) 
Reverse primer (3` to 5`) 
UBE2Z, NM_023079.3 Reference gene 
GCAGAGCATGTCTGGCATAG 
TTCTCCTTCTGCCAAAACAAA 
PGK1, NM_000291.3 Reference gene 
TGCATCTCCACTTGGCATTA 
TGGGATCTTGAAGAATGTATGC 
SRRM1, NM_005839.3 Reference gene 
GGAAATCCTTGGGTTTGAAGA 
GGCCACAGTTCTCCCATAAA 
COX4I1, NM_001861.2 Reference gene 
GGCACTGAAGGAGAAGGAGA 
GGGCCGTACACATAGTGCTT 
B2M, NM_004048 
DE gene determined 
by LO-BaFL / SAM 
GATGAGTATGCCTGCCGTGTG 
CAATCCAAATGCGGCATCT 
ACTG1, NM_001614 
DE gene determined 
by LO-BaFL / SAM 
AGAGGCTGGCAAGAACCAGTTGTT 
CAATGACGTGTTGCTGGGGCCT 
DYNLT1, NM_006519.1 
DE gene determined 
by TM4  
CCAGCCTATGGCCTTTCTCCTTTTGT 
CAACGCAGGCTGCAGGTGAC 
SKIV2L2, NM_015360.4 
DE gene determined 
by TM4  
TGCAGAAGGAATCACCAAAA 
ATGGGAGAACCAAATCCACA 
C12orf35, NM_018169.3 
DE gene determined 
by TM4  
CGGGGAAACAAGGTATTTGA 
TTCACATCACAGTGGGCATT 
TARDBP, NM_007375.3 
DE gene determined 
by TM4 
TTTGCTGCAGTTCTGTGTCC 
TCCATCTCAAAAGGGTCAAAA 
ILKAP, NM_030768.2 
Cross-hybridizing 
gene with TARDBP 
CACAGGAGTACACAAAACACAC 
TGCGGATAGGGCACTGAG 
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RNA quantification/ Quality 
assessment 
cDNA synthesis (Reverse 
transcription) 
Primer design 
qRT PCR 
 
Figure 2.1 Schematic diagram of the experimental design 
 
The GeneAmp® PCR System 9700 from Applied Biosystems [88] was set up to the 
following profile: the initial DNA denaturation at 95° C for 5 minutes; 30 cycles of 
denaturation at 94° C for 30 seconds, primer annealing at 57° C for 30 seconds and 
extension at 72° C for 30 seconds; a final elongation at 72° C for 4 minutes and a 4° C 
hold. 
Primer design and synthesis 
The primers were designed using Primer3 software [89] in combination with NCBI 
Primer-BLAST [90] to check for the specificity. Whenever possible (exceptions are 
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discussed below), the primers were designed to bridge the positions occupied by the 
corresponding Agilent probes, in order to account for sensitivity to transcriptional 
isoforms. Primers were purchased in dry form from Eurofins mwg|operon [91] and 
resuspended in DNA Suspension Buffer; concentrations were verified with the Nanodrop 
spectrophotometer, length was gel-verified using 12% Acrylamide in 1X TBE buffer 
[85]. PCR performance was checked with the cDNA made from the control RNA. PCR 
conditions were optimized by changing the Mg++ concentration in a range of 2.5 – 4.0 
µM, the annealing temperature in interval 55 to 60° C or the dNTP mixture concentration 
from 2.5 µM to 3.5 µM. Where necessary new primers were designed and run again 
through the QC protocol mentioned above. The list of primers and their designed 
sequences are provided in Table 2.1. 
qRT-PCR assay 
Before proceeding with qRT-PCR assays with patient samples, we performed a 
quality-control process, using the reference samples, for each gene product in order to  
optimize the PCR reaction conditions. By adjusting the primer annealing temperature, the 
concentration of Mg++ or of the dNTP mixture concentration within the parameters 
described above, we amplified products with similar efficiency using a common set of 
PCR reaction and cycling conditions. These are: annealing temperature = 57° C; Mg++ 
concentration = 3.5 µM; dNTP mixture concentration = 2.5 µM; primer mixture 
concentration = 5.0 µM. 
The quantification consistency was verified using parallel reactions, taking PCR 
reagents from a master mix to amplify the gene product reference at known 
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concentrations against a mass-titration of a sample’s cDNA product [51]. We used the 
following reagents: 10.0 µl/well of iQTM SYBR® Green Supermix from Bio-Rad [80] that 
includes 2X reaction buffer with dNTPs, iTaq DNA Polymerase, 6mM MgCl2, SYBR 
Green I, fluorescein and stabilizers according to the BIO-RAD specifications [80]; 
forward and reversed primer mixture (2.0 µl/well at 5 mM); 5.0 µl/well of template 
(either the standard gene, the unknowns or Accugene water-for the negative controls),  
and 3.0 µl/well Accugene water in final reaction volumes of 20.0 µl/well. Titration series 
were set up as follows: six 10- fold serial dilutions of the gene product reference and of 
the samples, in triplicates, with negative controls in all series to identify any cross-
contamination problems. The reactions were set up in 96-well clear Multiplate® PCR 
Plates, covered with iCycler iQTM Optical Tape from BIO-RAD [80]. The instrument 
employed for these reactions was MyiQ Single-Color Real-Time PCR Detection System 
from BIO-RAD [80]. We used a 2-step protocol with the following profile: Cycle 1: (1X) 
step 1: 95.0ºC for 03:00; Cycle 2: (40X) step 1: 94.0ºC for 00:15; step 2: 57.0ºC for 00:30 
(data collection and real-time analysis enabled); step 3: 72.0ºC for 00:15; Cycle 3: (1X) 
step 1: 95.0ºC for 01:00; Cycle 4: (1X)  step 1: 55.0ºC for 01:00. 
The data were analyzed using the relative quantification method applied for reactions 
with different efficiencies, as described by Pfaffl [81]. According to this method, the 
relative expression ratio is calculated with formula: 
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where: Etarget = real time PCR efficiency of a target gene transcript;  
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       Eref = real time PCR efficiency of a reference gene transcript; 
       ∆Cttarget = Ct deviation of control - sample of the target gene; 
       ∆Ctref = Ct deviation of control - sample of the reference gene. 
The corresponding real-time PCR efficiency of one cycle in the exponential phase was 
calculated, according to equation:  
                                        E =10[−1/ slope]
were the slope was determined automatically by the machine software [81]. 
 A standard curve is derived from serial dilutions, in our case six-point ten-fold 
dilutions and running standards in triplicates. Initial concentrations of standards and 
specific samples (unknowns), in logarithmic scale (base 10) are plotted against crossing 
points (Ct values). The regression coefficient R is calculated and adjusted for fitting the 
standards and unknowns: the greater and closer to 1 value of R, the better fit and thus, the 
better efficiency. We used the median value of efficiencies for Eref . The summarized 
results are shown in Table 2.2 and selected standard curves can be found in Figure 2.2. 
  Table 2.2 Relative expression ratio for DE genes. 
 
Gene Symbol Gene Accession Expression Ratio 
ACTG1 NM_001614 48.5 
SKIV2L2 NM_015360.4 37.3 
C12orf35 NM_018169.3 22.4 
B2M NM_004048 18.2 
DYNLT1 NM_006519.1 17.4 
ILKAP NM_030768.2 8.8 
TARDBP NM_007375.3 5.6 
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2.3 Results and Discussions 
We observed significant differential expression ratios for ACTG1, SKIV2L2, C12 
orf35, B2M and DYNLT1 and differential but smaller differences in the values for ILKAP 
and TARDBP. Our experimental results are in good agreement with very recent findings 
by Mougeot et al. [75] showing, by computational methods, that SKIV2L2, C12orf35, 
DYNLT1 were differentially expressed in PBLs samples from patients with sALS vs. 
Normals. 
 It is also confirmed here, as in previous studies, that TARDBP is among the genes 
with differential expression for ALS [8, 12]. The present work confirms the differential 
expression of three previously unreported genes (ACTG1, B2M, ILKAP) as determined by 
the LO-BaFL pipeline, with differential expression in the PBL samples from ALS 
patients vs. Controls.  
 Some of the TM4 genes were DE – that is LO-BaFL may exclude some genes that are 
actually DE, due to multiple and strict filtering steps, but the example of TARDBP and 
its cross-hybridizing gene, ILKAP, highlights why only TM4 is not efficient. In fact using 
both and then confirming the predictions with qRT-PCR may be the only way to be 
complete (pursuing mechanisms), while LO-BaFL is probably best for robust diagnostic 
predictions (less complete, but more likely to be right). 
2.4 Conclusions 
 Testing of 12 genes with qRT-PCR, confirmed the microarray observations and most 
of our computational predictions when applying LO-BaFL and comparative methods for 
microarray analysis: ACTG1, SKIV2L2, C12orf35, B2M, DYNLT1, TARDBP, ILKAP  
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(a) (b)  
    (c) (d) 
 Figure 2.2 qRT-PCR standard curves for selected genes.(a) ACTG1; (b) DYNLT1; (c) 
ILKAP; (d) SKIV2L2. 
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were found to have higher expression ratio in patients with ALS vs. Healthy Controls. 
This confirms the results of previous and more recent studies [8, 12, 75, 92], with 
additional new candidate biomarkers in the genes ACTG1, B2M, ILKAP.
 
 
 
 
 
Chapter 3: SEARCHING FOR SEQUENCE VARIANTS ASSOCIATED WITH 
DIFFERENTIALLY EXPRESSED GENES DETERMINED BY LO-BaFL AND 
COMPARATIVE METHODS 
 
 
3.1 Introduction 
Although in the absence of a known cause no definitive statement can be made, it is 
thought at this time that ALS is a complex disease. This means that the condition is not 
determined by genetic mutations in a single gene, but is the result of accumulating errors 
(since it is usually late in onset, like many cancers) that change interactions between 
multiple genes. Sequence variants within transcripts, as distinct from their regulatory 
regions, are broadly of two types: single nucleotide polymorphisms that may or may not 
create a minor change in the coding sequence of a protein and may or may not change the 
processing of the transcript, and alternative splice forms that result in different exon 
presence and thus a significantly different protein form, possibly leading to different 
modification and localization. A likely example of the latter is seen with the TARDBP 
protein, for which aggregates are seen in all post-mortem sALS patients. Studies of 
genetic markers, such as SNPs, through linkage mapping or genome wide association 
studies (GWAS), can reveal genes associated with a particular disease if the association is 
sufficiently strong [16, 18, 93-95]. It is believed that single nucleotide polymorphisms are 
responsible for most of the genetic variation in humans, on average one site per 300 bases 
[96]. This variation conditions all biochemical responses and influences the variable 
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responses seem for many human diseases, e.g.: altered responses to pathogens, chemicals, 
drugs and vaccines. Tuning treatments to specific variants may lead to interventions for 
genetic diseases and in gene therapy [97].  However, to uncover relatively weak effects 
over many gene combinations against a wide range of backgrounds requires sample sizes 
in the tens of thousands; with polygenic conditions the correct stratification of patients is 
often problematic. Worldwide the number of patients with ALS barely meets the required 
number and the majority will not be eligible for GWAS studies, for a variety of reasons. 
Thus studies of genetic variants present in ALS patients usually focus on genes with 
interesting molecular phenotypes, from expression of the transcript or expression and 
localization of the protein product. We investigated sequence variants in the samples that 
passed the quality criteria that occurred in our list of differentially expressed genes 
identified in Chapter 1 and Chapter 2. 
We formulate the hypothesis that there are SNPs present in the differentially 
expressed genes that correlate to the disease state. Wet lab analysis of DNA from 10 
patient samples (n=5, diseased; n=5, normals) were tested for the presence of sequence 
polymorphisms in specific regions of DE genes. Several of these genes have known 
SNPs, although they have not been linked to sALS, including ACTG1, B2M and 
SLC25A3; ACTG1 is linked to muscle development, and one study showed reduced 
expression levels of the gene in an animal model correlating with human muscle 
weakness and myopathies [98]; B2M is found in amyloid particles characteristic of 
Alzheimer’s disease:  its structure can adopt a fibrillar configuration seen in amyloid 
structures in certain pathological states [99]. We selected FTH1 because defects in 
45 
 
ferritin proteins are associated with several neurodegenerative diseases [100, 101], as 
well as two ribosomal proteins, RPS10A and RPL21, and TARDBP, which has been 
extensively studied at the protein level in both familial and sporadic ALS [108-111]. The 
genes and their dbSNP IDs are listed in Table 3.1. Of these genes, SLC25A3 is a 
mitochondrial phosphate carrier (PiC), was of particular interest, because Mayr et al. 
[102] have shown that a deficiency in PiC in muscle is caused by a homozygous mutation 
in the alternatively spliced exon 3A of the gene. By replacing the guanine in position 215 
with adenine (215G-to-A in the mRNA), a glycine becomes a glutamate (Gly72-to-Glu in 
the protein). The consequences are severe, including hypertrophic cardiomyopathy, 
muscular hypotomia, and lactic acidosis [102]. Studies on a separate glutamate solute 
carrier gene, SLC1A2 did reveal an association with sALS [103-105]. Since LO-BAFL 
detected differential expression in the gene and the phenotype is relevant to the disease 
state we sequenced part of SLC25A3.  
Table 3.1. Selected genes with known SNPs for sequencing 
 and their dbSNP IDs. 
Gene Symbol Accession Exon / dbSNP ID 
B2M NM_004048 Exon 1 / rs104894481  
ACTG1 NM_001614 Exon 3 / rs28999111 
  Exon 5 / rs28999112 
  Exon 6 / rs104894547 
SLC25A3 NM_005888 Exon 3A / rs104894375 
 
3.2 Materials and Methods  
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Due to limited materials, only ten PBLs samples from patients with sALS (n=5) and 
Healthy Controls (n=5), were available from the original lot. Samples are described in 
detail in Chapter 1. Preparation for Sanger sequencing [106] required cDNA synthesis 
and PCR amplification: these protocols were described in Chapter 2. Design of 
amplification primers followed methods similar to those used for qRT-PCR (see Figure 
3.1). From the list with differentially expressed genes (see Chapter 1) we targeted ten 
exons as follows: five for expressed genes with identified SNPs, (Table 3.1), and in 
addition, the exons comprising the Agilent probes for corresponding DE genes. The 
complete information for the sequenced genes (exon), primer sequences, annealing 
temperatures and product size are given in Table 3.2. 
Obtained sequences were BLAST-ed against target sequences, with NCBI bl2seq, to 
check for similarity. The electropherograms were visualized and analyzed with FinchTV 
[107], a free tool for DNA trace view with enhanced capabilities for BLAST, reverse 
complement, and heterozygote detection.  
3.3 Results and Discussions 
We analyzed the outcome of 200 sequencing reactions to identify any sequence 
variants in our selected exons. There were no mutations that consistently segregated with 
the disease samples. A novel mutation in exon3 of the ACTG1 gene, was found. This 
exon was screened for the SNP rs28999111, which has the sequence: 
CGACATGGAGAAGATCTGGCACCACA[C/T]CTTCTACAACGAGCTGCGCGTGGCC 
Shown below, the target amplified was designed to include the known mutation 
(shown in blue, the primer sites are also highlighted).  
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TGACCCTGAAGTACCCCATTGAGCATGGCATCGTCACCAACTGGGACGACATGGAGAAGATCTGGCAC
CACACCTTCTACAACGAGCTGCGCGTGGCCCCGGAGGAGCACCCAGTGCTGCTGACCGAGGCCCCCCTG
AACCCCAAGGCCAACAGAGAGAAG 
 
Table 3.2 PCR primers for sequencing purposes. Note: The gene symbol in column 1 is 
followed by the exon number, parenthesis specifying the presence of a SNP or the fact 
that the primer was designed around the Agilent probe; F, R denote forward and reversed. 
 
Exon Sequence Annealing temperature (ºC) 
Product 
size (bp) 
B2M-e2(probe)-F GTGTCTGGGTTTCATCCATCCGAC 57.5 176 
B2M-e2(probe)-R ACATGGTTCACACGGCAGGCAT 59.3  
FTH1-e4(probe)-F CCCCATAGCCGTGGGGTGACT 60 170 
FTH1-e4(probe)-R CCCAAGACCTCAAAGACAACACCTG 58  
ACTG1-e3(SNP)-F TGACCCTGAAGTACCCCATT 59 161 
ACTG1-e3(SNP)-R CTTCTCTCTGTTGGCCTTGG 60  
ACTG1-e5(SNP)-F GTATGGAATCTTGCGGCATC 60 152 
ACTG1-e5(SNP)-R GGTGATCTCCTTCTGCATCC 60  
ACTG1-e6(SNP)-F TGAGGCTAGCATGAGGTG TG 56.8 169 
ACTG1-e6(SNP)-R CCTTCCAGCAGATGTGGATT 55  
RPL21-e2,3(probe)-F AGTTGTTCCTTTGGCCACATA 59.5 162 
RPL21-e2,3(probe)-R TTTACAACAATGCCAACAGCA 60  
RPS10-e1(probe)-F CTCACAAGAGGGGAAGCTGA 60.5 151 
RPS10-e1(probe)-R TTTACTGAGGTGGCTGACCA 60  
SLC25A3-e3A(SNP)-F CATTCCAGTGGCCTTAGTCA 54.5 203 
SLC25A3-e3A(SNP)-R TGCAAAACAAACCTGCATTC 52.5  
SLC25A3-e8(probe)-F 
AGCTGTGGCACAACACATACAGC 
59 152 
SLC25A3-e8(probe)-R AGCCAAGGAAAGTCGGAGCCCA 58  
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Primer design 
 
 
PCR 
 
 
                                 
QC on 12% PAGE  
                
Ethanol precipitation 
 
 
 
Nanodrop quantification 
 
 
Bi-directional sequencing 
 
 
Ethanol precipitation 
 
 
Electrophoresis 
 
                              Figure 3.1. The flow chart for sequencing assay  
 
The electropherograms were analyzed with FinchTV (PerkinElmer/ Geospiza), by 
which we were able to resolve the nucleotides originally shown as ‘ambiguous’ 
(highlighted in red below); several examples are given. The small grey letters above the 
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alignment represent either the original majority call from the ABI software or minor 
known alleles. The nucleotides in green are the replacement calls we made that agree 
with the known major alleles, and the ‘C’ nucleotide in blue is the location of the dbSNP-
characterized variant (present in all of our samples). 
The nucleotides shown in magenta highlight the newly identified mutation. Text 
labels include F and R for the forward and reverse reactions and HC# or ALS# for the 
healthy control and ALS sample number.  
F-HC7; Score = 170 bits (188), Expect = 7e-48, Identities = 105/111 (95%), Gaps = 
1/111 (1%), Strand=Plus/Plus.  
                    a                       c        c     c  g                              
Query  20   ATGGAGAAGATCTGGCACCACACCTTCTACAATGAGCTGCGTGTGGCTCCCGAGGAGCAC  78 
            |||||||| ||||||||||||||||||||||| |||||||| ||||| || ||||||||| 
 Sbjct  51  ATGGAGAAGATCTGGCACCACACCTTCTACAACGAGCTGCGCGTGGCCCCGGAGGAGCAC  110 
R-HC7:Score = 187 bits (206), Expect = 1e-52, Identities = 114/121 (94%), Gaps = 
0/121 (0%), Strand=Plus/Minus.   
                    t           c  g     g        g 
Query  13   AGCAGCACGGGGTGCTCCTCGGGAGCCACACGCAGCTCATTGTAGAAGGTGTGGTGCCAG  72 
            |||||||| ||||||||||| || ||||| |||||||| ||||||||||||||||||||| 
Sbjct  121  AGCAGCACTGGGTGCTCCTCCGGGGCCACGCGCAGCTCGTTGTAGAAGGTGTGGTGCCAG  62 
         
              c                                a 
Query  73   ATTTTCTCCATGTCGTCCCAGTTGGTGACGATGCCGTGCTCAATGGGGTACTTCAGGGTC  132 
            || |||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  61   ATCTTCTCCATGTCGTCCCAGTTGGTGACGATGCCATGCTCAATGGGGTACTTCAGGGTC  2 
F-HC7; Score = 170 bits (188), Expect = 7e-48, Identities = 105/111 (95%), Gaps = 
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1/111 (1%), Strand=Plus/Plus.  
                    a                       c        c     c  g                               
Query  20   ATGGAGAAGATCTGGCACCACACCTTCTACAATGAGCTGCGTGTGGCTCCCGAGGAGCAC  78 
            |||||||| ||||||||||||||||||||||| |||||||| ||||| || ||||||||| 
 Sbjct  51  ATGGAGAAGATCTGGCACCACACCTTCTACAACGAGCTGCGCGTGGCCCCGGAGGAGCAC  110 
R-HC7:Score = 187 bits (206), Expect = 1e-52, Identities = 114/121 (94%), Gaps = 
0/121 (0%), Strand=Plus/Minus.   
                    t           c  g     g        g 
Query  13   AGCAGCACGGGGTGCTCCTCGGGAGCCACACGCAGCTCATTGTAGAAGGTGTGGTGCCAG  72 
            |||||||| ||||||||||| || ||||| |||||||| ||||||||||||||||||||| 
Sbjct  121  AGCAGCACTGGGTGCTCCTCCGGGGCCACGCGCAGCTCGTTGTAGAAGGTGTGGTGCCAG  62 
              c                                a 
Query  73   ATTTTCTCCATGTCGTCCCAGTTGGTGACGATGCCGTGCTCAATGGGGTACTTCAGGGTC  132 
            || |||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  61   ATCTTCTCCATGTCGTCCCAGTTGGTGACGATGCCATGCTCAATGGGGTACTTCAGGGTC  2 
F-ALS1: Score = 188 bits (208), Expect = 3e-53,Identities = 116/121 (96%), Gaps = 
2/121 (2%), Strand=Plus/Plus. 
                  -  -                                c              c 
Query  12   CTGGGACGACATGGAGAAGATCTGGCACCACACCTTCTACAATGAGCTGCGCGTGGCTCC  69 
            |||||| || |||||||||||||||||||||||||||||||| |||||||||||||| || 
Sbjct  41   CTGGGACGACATGGAGAAGATCTGGCACCACACCTTCTACAACGAGCTGCGCGTGGCCCC  100 
R-ALS1:  Score = 179 bits (198),  Expect = 6e-50, Identities = 114/121 (94%), 
Gaps = 2/121 (2%), Strand=Plus/Minus. 
 
                  -          -     a     a        g 
Query  11   AGCAGCACTGGGTGCTCCTCCGGGGCCACACGCAGCTCATTGTAGAAGGTGTGGTGCCAG  68 
51 
 
            |||||| |||||||||| ||||| ||||| |||||||| ||||||||||||||||||||| 
Sbjct  121  AGCAGCACTGGGTGCTCCTCCGGGGCCACGCGCAGCTCGTTGTAGAAGGTGTGGTGCCAG  62 
              t                                a 
Query  69   ATCTTCTCCATGTCGTCCCAGTTGGTGACGATGCCGTGCTCAATGGGGTACTTCAGGGTC  128 
            || |||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  61   ATCTTCTCCATGTCGTCCCAGTTGGTGACGATGCCATGCTCAATGGGGTACTTCAGGGTC  2 
In 9 of the 10 samples analyzed, the cytosine in position 350 of the ACTG1 gene, 
in exon 3, is replaced by a thymine (c.350C-to-T): 
TCTGGCACCACACCTTCTACAA[C/T]GAGCTGCGCGTGGCCCCGGAGGAGCAC 
To our knowledge, the SNP has not been reported in the literature. It cannot be 
associated with the disease state since is present in both sample classes. To validate the 
amino acid change (ACG ATG equivalent to THR MET), if present, further protein 
assays are necessary, for which we do not have materials at present. Selected screenshots 
showing the presence of this mutation are given in Figure 3.2.  
The results for the rest of the genes, by the respective exons (see Table 3.2) are 
presented below. The colors follow the scheme described above.  
FTH1, with the target sequence: 
CCCCATAGCCGTGGGGTGACTTCCCTGGTCACCAAGGCAGTGCATGCATGTTGGGGTTTCCTTTACCTT
TTCTATAAGTTGTACCAAAACATCCACTTAAGTTCTTTGATTTGTACCATTCCTTCAAATAAAGAAATTTG
GTACCCAGGTGTTGTCTTTGAGGTCTTGGG  
For most of the obtained sequences, the identity with the target was between 96 - 
99%, of which 6 were perfect matches (100% identity); thus no SNP was present. 
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      (a)      (b) 
Figure 3.2 Electropherograms showing the presence of a novel mutation (the highlighted 
section) in forward (a) and reversed sequencing (b) for sample HC7. 
 
F-HC7: Score = 232 bits (256), Expect = 3e-66, Identities = 129/130 (99%), Gaps = 
0/130 (0%), Strand=Plus/Plus. 
                                                   - 
Query  13   TGCATGCATGTTGGGGTTTCCTTTACCTTTTCTATAAGTTGTACCAAAACATCCACTTAA  72 
            |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  41   TGCATGCATGTTGGGGTTTCCTTTACCTTTTCTATAAGTTGTACCAAAACATCCACTTAA  100 
R-HC7: Score = 208 bits (230), Expect = 3e-59, Identities = 122/126 (97%), Gaps = 
1/126 (1%), Strand=Plus/Minus. 
                                    N    N-      N 
Query  18   TGAAGGAATGGTACAAATCAAAGAACTTAAGTGGATGTTTTGGTACAACTTATAGAAAAG  76 
            || ||||  |||||| |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  126  TGAAGGAATGGTACAAATCAAAGAACTTAAGTGGATGTTTTGGTACAACTTATAGAAAAG  67                                
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F-ALS1: Score = 242 bits (268), Expect = 6e-69, Identities = 135/136 (99%), Gaps = 
0/136 (0%), Strand=Plus/Plus. 
              N 
Query  9    AGGCAGTGCATGCATGTTGGGGTTTCCTTTACCTTTTCTATAAGTTGTACCAAAACATCC  68 
            || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  35   AGGCAGTGCATGCATGTTGGGGTTTCCTTTACCTTTTCTATAAGTTGTACCAAAACATCC  94 
R-ALS1: Score = 226 bits (250), Expect = 5e-64, Identities = 131/134 (98%), 
Gaps = 2/134 (1%), Strand=Plus/Minus. 
                         ga 
Query  9    TCTTTATTTGAGG--ATGGTACAAATCAAAGAACTTAAGTGGATGTTTTGGTACAACTTA  66 
            ||||||||||| |  ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  134  TCTTTATTTGAAGGAATGGTACAAATCAAAGAACTTAAGTGGATGTTTTGGTACAACTTA  75 
For B2M-exon 2, the target sequence that includes the Agilent probe is: 
GTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGT
GGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCA
CTGAAAAAGATGAGTATGCCTGCCGTGTGAACCATGT 
This sequence alignment with the oligonucleotide obtained after sequencing shows a 
very good identity (96 - 99 %) with the exon, and the visual inspection of the 
electropherogram did not suggest the presence of any sequence variants. Below we 
present selected examples. 
F-HC12: Score = 219 bits (242), Expect = 2e-62, Identities = 128/130 (98%), Gaps = 
2/130 (2%), Strand=Plus/Plus. 
                        -       - 
Query  16   ATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTT  73 
            ||||||||||| ||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  47   ATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTT  106 
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R-HC12: Score = 244 bits (270), Expect = 1e-69, Identities = 139/140 (99%), Gaps = 
1/140 (1%), Strand=Plus/Minus. 
                      - 
Query  9    GTGGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCCTTGCTGAAAGACAAG  67 
            |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  140  GTGGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCCTTGCTGAAAGACAAG  81 
F-ALS8: Score = 219 bits (242), Expect = 2e-62, Identities = 128/130 (98%), Gaps = 
2/130 (2%), Strand=Plus/Plus. 
                       -       - 
Query  15   ATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTT  72 
            ||||||||||| ||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  47   ATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAGGACTGGTCTT  106 
R-ALS8: Score = 208 bits (230), Expect = 8e-59, Identities = 132/138 (96%), Gaps = 
4/138 (3%), Strand=Plus/Minus. 
                   c                    -    -                 - 
Query  8    GGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCCTTGCTGAAAGACAAGTC  64 
            ||||||| |||||||||||||||||||| |||| ||||||||||||||||| |||||||| 
Sbjct  138  GGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCCTTGCTGAAAGACAAGTC  79 
For ACTG1- exon 5, with SNP ID: rs28999112 and corresponding sequence: 
GGAATCTTGCGGCATCCACGAGACCA[C/T]CTTCAACTCCATCATGAAGTGTGAC;   
the target sequence was designed to incorporate the mutation: 
GTATGGAATCTTGCGGCATCCACGAGACCACCTTCAACTCCATCATGAAGTGTGACGTGGACATCCGC
AAAGACCTGTACGCCAACACGGTGCTGTCGGGCGGCACCACCATGTACCCGGGCATTGCCGACAGGATG
CAGAAGGAGATCACC 
In our samples no polymorphism was seen as all of them contained the ancient allele 
(C) and 97-100 % identities were observed. Selected examples are given here. 
F-HC3: Score = 185 bits (204), Expect = 3e-52, Identities = 109/112 (97%), Gaps = 
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1/112 (1%), Strand=Plus/Plus. 
                    a 
Query  9    CATCATGA-GTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACGGTGCTGTCGGG  67 
            |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  41   CATCATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACGGTGCTGTCGGG  100 
                           c           c 
Query  68   CGGCACCACCATGTATCCGGGCATTGCTGACAGGATGCAGAAGGAGATCACC  119 
            ||||||||||||||| ||||||||||| |||||||||||||||||||||||| 
Sbjct  101  CGGCACCACCATGTACCCGGGCATTGCCGACAGGATGCAGAAGGAGATCACC  152 
R-HC3: Score = 187 bits (206), Expect = 8e-53, Identities = 108/110 (98%), Gaps = 
1/110 (1%), Strand=Plus/Minus 
              N 
Query  11   GGTGGTGC-GCCCGACAGCACCGTGTTGGCGTACAGGTCTTTGCGGATGTCCACGTCACA  69 
            || ||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  110  GGTGGTGCCGCCCGACAGCACCGTGTTGGCGTACAGGTCTTTGCGGATGTCCACGTCACA  51 
                                                                      
Query  70   CTTCATGATGGAGTTGAAGGTGGTCTCGTGGATGCCGCAAGATTCCATAC  119 
            |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  50   CTTCATGATGGAGTTGAAGGTGGTCTCGTGGATGCCGCAAGATTCCATAC  1 
F-ALS2: Score = 190 bits (210), Expect = 1e-53, Identities = 110/112 (98%), Gaps = 
1/112 (1%), Strand=Plus/Plus.  
                    - 
Query  10   CATCATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACGGTGCTGTCGGG  68 
            |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  41   CATCATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACGGTGCTGTCGGG  100 
                           c 
Query  69   CGGCACCACCATGTATCCGGGCATTGCCGACAGGATGCAGAAGGAGATCACC  120 
            ||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  101  CGGCACCACCATGTACCCGGGCATTGCCGACAGGATGCAGAAGGAGATCACC  152 
 
R-ALS2: Score = 192 bits (212), Expect = 5e-54, Identities = 110/111 (99%), Gaps = 
56 
 
1/111 (1%), Strand=Plus/Minus.                     
                     - 
Query  11   TGGTGGTGCCGCCCGACAGCACCGTGTTGGCGTACAGGTCTTTGCGGATGTCCACGTCAC  69 
            ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  111  TGGTGGTGCCGCCCGACAGCACCGTGTTGGCGTACAGGTCTTTGCGGATGTCCACGTCAC  52 
 
Query  70   ACTTCATGATGGAGTTGAAGGTGGTCTCGTGGATGCCGCAAGATTCCATAC  120 
            ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  51   ACTTCATGATGGAGTTGAAGGTGGTCTCGTGGATGCCGCAAGATTCCATAC  1 
ACTG1 was also screened for the SNP reported in exon 6, rs104894547. Therefore, 
we designed the target sequence to include this mutation. 
TGAGGCTAGCATGAGGTGTGTGCATTTGCCAGGGGCAAATTTCTATTCTCAATTAACCCATGCAGCAAA
TGCTACGCATCTGCTGAGTCCGTTTAGAAGCATTTGCGGTGGACGATGGAGGGGCCCGACTCGTCGTACT
CCTGCTTGCTAATCCACATCTGCTGGAAGG 
F-HC14: Score = 188 bits (208), Expect = 8e-53, Identities = 119/128 (93%), Gaps = 
4/128 (3%), Strand=Plus/Plus.             
                        a- 
Query  13   TCTATTCTCATT--ACCCATGCAGCAAATGCTACGCATCTGCTGAGTCCGTTTAGAANAN  70 
            |||||||||| |  |||||||||||||||||||||||||||||||||||||||||||    
Sbjct  42   TCTATTCTCAATTAACCCATGCAGCAAATGCTACGCATCTGCTGAGTCCGTTTAGAAGCA  101 
 
Query  71   T--GCGGTGGACGATGGAGGGGCCCGACTCGTCGTACTCCTGCTTGCTAATCCACATCTG  128 
            |  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  102  TTTGCGGTGGACGATGGAGGGGCCCGACTCGTCGTACTCCTGCTTGCTAATCCACATCTG  161 
 
 
R-HC14: Score = 230 bits (254), Expect = 2e-65, Identities = 132/135 (98%), Gaps = 
1/135 (1%), Strand=Plus/Minus. 
                 N N 
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Query  9    GACGAAGTCGGGCCCCTCCATCGTCCACCGCAAATGCTTCTAAACGGACTCAGCAGATGC  68 
            ||||| | |||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  134  GACGA-GTCGGGCCCCTCCATCGTCCACCGCAAATGCTTCTAAACGGACTCAGCAGATGC  76 
F-ALS8: Score = 223 bits (246), Expect = 4e-63, Identities = 129/132 (98%), Gaps = 
1/132 (1%), Strand=Plus/Plus. 
                N         - 
Query  10   AATTTCTATTCTCAATTAACCCATGCAGCAAATGCTACGCATCTGCTGAGTCCGTTTAGA  68 
            |||| ||||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  38   AATTTCTATTCTCAATTAACCCATGCAGCAAATGCTACGCATCTGCTGAGTCCGTTTAGA  97 
                          g 
Query  69   AGCATTTGCGGTGGACGATGGAGGGGCCCGACTCGTCGTACTCCTGCTTGCTAATCCACA  128 
            |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  98   AGCATTTGCGGTGGCCGATGGAGGGGCCCGACTCGTCGTACTCCTGCTTGCTAATCCACA  157 
R-ALS8: Score = 219 bits (242), Expect = 2e-62, Identities = 128/131 (98%), Gaps = 
1/131 (1%), Strand=Plus/Minus. 
                    c                    - 
Query  11   GAGTCGGGGCCCTCCATCGTCCACCGCAAATGCTTCTAAACGGACTCAGCAGATGCGTAG  69 
            |||||||| |||||||||| ||||||||| |||||||||||||||||||||||||||||| 
Sbjct  131  GAGTCGGGCCCCTCCATCGGCCACCGCAAATGCTTCTAAACGGACTCAGCAGATGCGTAG  72 
For RPL21, the target sequence was designed around the Agilent probe sequence, 
where no SNPs were previously reported.   
AGTTGTTCCTTTGGCCACATATATGCGAATCTATAAGAAAGGTGATATTGTAGACATCAAGGGAATGG
GTACTGTTCAAAAAGGAATGCCCCACAAGTGTTACCATGGCAAAACTGGAAGAGTCTACAATGTTACCCA
GCATGCTGTTGGCATTGTTGTAAA 
Sequencing assays did not show any new sequence variant, the two-sequence 
alignment providing identities in 90 – 100 % interval. Selections for two samples, in both 
forward and reversed directions, are presented. 
F-HC10: Score = 214 bits (236), Expect = 7e-61, Identities = 122/123 (99%), Gaps = 
58 
 
1/123 (1%), Strand=Plus/Plus. 
Query  10   AGGTGATATTGTAGACATCAAGGGAATGGGTACTGTTCAAAAAGGAATGCCCCACAAGTG  68 
            |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  40   AGGTGATATTGTAGACATCAAGGGAATGGGTACTGTTCAAAAAGGAATGCCCCACAAGTG  99 
R-HC10:  Score = 208 bits (230), Expect = 3e-59, Identities = 119/120 (99%), Gaps = 
1/120 (1%), Strand=Plus/Minus. 
                 c 
Query  14   TCTTC-AGTTTTGCCATGGTAACACTTGTGGGGCATTCCTTTTTGAACAGTACCCATTCC  72 
            ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  TCTTCCAGTTTTGCCATGGTAACACTTGTGGGGCATTCCTTTTTGAACAGTACCCATTCC  62 
F-ALS6: Score = 201 bits (222), Expect = 4e-57, Identities = 115/116 (99%), Gaps = 
1/116 (1%), Strand=Plus/Plus. 
Query  15   ATTGTAGACATCAAGGGAATGGGTACTGTTCAAAAAGGAATGCCCCACAAGTGTTACCAT  73 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  47   ATTGTAGACATCAAGGGAATGGGTACTGTTCAAAAAGGAATGCCCCACAAGTGTTACCAT  106 
R-ALS6: Score = 179 bits (198), Expect = 2e-50, Identities = 112/118 (95%), Gaps = 
2/118 (2%), Strand=Plus/Minus. 
                          at                                                                  
Query  22   CAGTTTTGCCATGGGGAACACTTGTGGGGGCATTCCTTTTTGAACAGTACCCATTCCCCT  81 
            ||||||||||||||  |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  116  CAGTTTTGCCATGGT-AACACTTGTGGGG-CATTCCTTTTTGAACAGTACCCATTCCCTT  59 
  
 
            g                       t 
Query  82   GATGTCTACAATATCACCTTTCTTAGAGATTCGCATATATGTGGCCAAAGGAACAACT  139 
            ||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  58   GATGTCTACAATATCACCTTTCTTATAGATTCGCATATATGTGGCCAAAGGAACAACT  1 
For RPS10, the target sequence comprising the Agilent probe is: 
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CTCACAAGAGGGGAAGCTGACAGAGATACCTACAGACGGAGTGCTGTGCCACCTGGTGCCGACAAGAA
AGCCGAGGCTGGGGCTGGGTCAGCAACCGAATTCCAGTTTAGAGGCGGATTTGGTCGTGGACGTGGTCA
GCCACCTCAGTAAA  
Although the presence of any sequence variant was not confirmed, we selected one of 
each HC / sALS sample to exemplify the sequence alignment query-to-target obtained 
with bl2seq. In general, 96 – 100% identities were found. 
F-HC14: Score = 188 bits (208), Expect = 2e-53, Identities = 109/111 (98%), Gaps = 
1/111 (1%), Strand=Plus/Plus. 
                     a                  a 
Query  11   GTGCTGTGCCACCTGGTGCCGACAAGAA-GCCGAGGCTGGGGCTGGGTCAGCAACCGAAT  69 
            ||||||||| |||||||||||||||||| ||||||||||||||||||||||||||||||| 
Sbjct  41   GTGCTGTGCCACCTGGTGCCGACAAGAAAGCCGAGGCTGGGGCTGGGTCAGCAACCGAAT  100 
R-HC14: Score = 187 bits (206), Expect = 9e-53, Identities = 111/114 (97%), Gaps = 
2/114 (2%), Strand=Plus/Minus. 
              N     a 
Query  8    GCCTCTAA-CTGGA-TTCGGTTGCTGACCCAGCCCCAGCCTCGGCTTTCTTGTCGGCACC  65 
            || ||||| ||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  114  GCCTCTAAACTGGAATTCGGTTGCTGACCCAGCCCCAGCCTCGGCTTTCTTGTCGGCACC  55 
F-ALS8: Score = 181 bits (200), Expect = 3e-51, Identities = 108/111 (97%), Gaps = 
2/111 (2%), Strand=Plus/Plus. 
                
 N-                 - 
Query  13   GTGCTGTGCCACCTGGTGCCGACAAGAAAGCCGAGGCTGGGGCTGGGTCAGCAACCGAAT  70 
            |||||||||  ||||||||||||||||| ||||||||||||||||||||||||||||||| 
Sbjct  41   GTGCTGTGCCACCTGGTGCCGACAAGAAAGCCGAGGCTGGGGCTGGGTCAGCAACCGAAT  100 
R-ALS8: Score = 183 bits (202), Expect = 1e-51, Identities = 105/106 (99%), Gaps = 
1/106 (1%), Strand=Plus/Minus. 
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                  a 
Query  15   ACTGGA-TTCGGTTGCTGACCCAGCCCCAGCCTCGGCTTTCTTGTCGGCACCAGGTGGCA  73 
            |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  106  ACTGGAATTCGGTTGCTGACCCAGCCCCAGCCTCGGCTTTCTTGTCGGCACCAGGTGGCA  47 
The gene in which we had the most interest, SLC25A3 was searched for the presence 
of SNPs in exon 3A (a previously reported mutation) and also in exon 8 where the 
Agilent probe used in microarray analysis was located. In regards to exon 3A, after 
repeated trials, where no probe signal was received from the DNA Analyzer, we 
concluded that this particular exon is not expressed in PBLs, but most probably is tissue 
specific. This result is concordant with work of Mayr et al. [102] and Shah et al.[108], 
who showed that exon 3A is expressed only in muscle, heart and thyroid tissues.  
For exon 8, only 80% of the sequencing reactions were successful, as for four of the 
samples no signal was detected. Since other sequencing from these samples were 
successful this may also indicate variant isoforms. In the sequences present no 
polymorphisms were detected. The designed target sequence is: 
CTCCGTGAAGGTCTACTTCAGACTTCCTCGCCCTCCTCCACCCGAGATGCCAGAGTCTCTGAAGAAGAA
GCTTGGGTTAACTCAGTAGTTAGATCAAAGCAAATGTGGACTGAATCTGCTTGTTGATCAGTGTTGAAGA
AAGTGCAAAAGGA 
A single example from a diseased sample is shown, since the control samples did not 
yield usable data.  
F-ALS1: Score = 179 bits (198), Expect = 1e-50, Identities = 111/115 (97%), Gaps = 
3/115 (3%), Strand=Plus/Plus. 
                  -                              g 
Query  8    CCCGAGGATGCCAGAGTCTCTGAAGAAGAAGCTTGGG-TTAACTCAGTAGTTAGATCAAA  67 
            |||||| |||||||||||||||||||||||||||||| |||||||||||||||||||||| 
Sbjct  41   CCCGAG-ATGCCAGAGTCTCTGAAGAAGAAGCTTGGG-TTAACTCAGTAGTTAGATCAAA  98 
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                    cc 
Query  68   GCAAATGTG-GACTGAATCTGCTTGTTGATCAGTGTTGAAGAAAGTGCAAAAGGA  122 
            ||||||||  ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  99   GCAAATGTG-GACTGAATCTGCTTGTTGATCAGTGTTGAAGAAAGTGCAAAAGGA  152 
R-ALS1: Score = 185 bits (204), Expect = 3e-52, Identities = 109/112 (97%), Gaps = 
1/112 (1%), Strand=Plus/Minus. 
                 c                          g 
Query  10   CAGTC-ACATTTGCTTTGATCTAACTACTGAGTTAACCCAAGCTTCTTCTTCAGAGACTC  68 
            ||||| |||||||||||||||||||||||||| ||||||||||||||||||||||||||| 
Sbjct  112  CAGTCCACATTTGCTTTGATCTAACTACTGAGTTAACCCAAGCTTCTTCTTCAGAGACTC  53 
                                                   g 
Query  69   TGGCATCTCGGGTGGAGGAGGGCGAGGAAGTCTGAAGTAAACCTTCACGGAG  120 
            ||||||||||||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  52   TGGCATCTCGGGTGGAGGAGGGCGAGGAAGTCTGAAGTAGACCTTCACGGAG  1 
PCR amplification failed to yield products for B2M (exon 1) and for TARDBP (exon 
8) in the regions selected. Since the primers and conditions had been reported as 
successful previously, and since microarray detection was well within the reliable range, 
this outcome is most probably due to sample degradation.  
3.4 Conclusions 
Direct sequencing was performed to screen for possible mutations in selected exons 
of differentially expressed genes determined by the LO-BaFL pipeline, for the five 
healthy controls and five diseased (sALS) samples for which we had good quality cDNA. 
In the majority of the products good quality sequence that matched database records was 
obtained and no polymorphisms were found. In one case we identified a novel mutation 
in exon 3 of ACTG1 gene, c.350 C-to-T, as follows: 
TCTGGCACCACACCTTCTACAA[C/T]GAGCTGCGCGTGGCCCCGGAGGAGCAC 
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Previous studies on this actin, gamma 1 gene showed the presence of several allelic 
variants related to hearing loss [109-112] (see Table 3.3).  
   Table 3.3 Allelic variants for ACTG1, from OMIM database. 
Number Phenotype Mutation dbSNP  
.0001 Deafness, autosomal dominant 20 THR89ILE rs28999111 
.0002 Deafness, autosomal dominant 20 LYS118MET rs104894544
.0003 Deafness, autosomal dominant 20 PRO332ALA rs104894545
.0004 Deafness, autosomal dominant 20 PRO264LEU rs104894546
.0005 Deafness, autosomal dominant 20 THR278ILE rs28999112 
.0006 Deafness, autosomal dominant 20 VAL370ALA rs104894547
 
Research on animal models that reduced expression levels of the gene correlate with 
human muscle weakness and myopathies [98], not surprising given the role of ACTG1 in 
skeletal muscle development. However, since we found this variant in what are labeled 
‘healthy controls’, it does not correlate with sALS.  
Further studies, at the protein level, are needed to shed light into possible protein 
changes. Since the exons show evidence of differential expression but no local SNP was 
present, the change is due to turnover or regulation, not to disturbed binding to the DNA 
probe from an uncharacterized SNP. So it might be worthwhile to sequence each of these 
genes in their entirety, including the regulatory regions. The changes might be due to 
changes in the transcription factors that bind those regions - that should be indicated by 
changes in other genes controlled by those factors. That is one type of pathway analysis, 
which is covered in the next chapter. 
 
 
CHAPTER 4: PATHWAY ANALYSIS 
 
 
4.1 Introduction 
As discussed in Chapter 3, Amyotrophic Lateral Sclerosis is a complex disease whose 
pathology and etiology have not been deciphered. While biomarker discovery can be 
pursued using patterns of expression-level change, described in Chapter 2, our eventual 
goal must be to understand the mechanism underlying its biology. Since this is a motor-
neuron disease it is unlikely that the circulating blood cells are directly affected by the 
causative agent, but subsets of these cells respond to signals from decaying cells and 
these signals may provide clues to the original source of the pathology. Having confirmed 
increased levels of expression of marker genes, the cause for such increases was 
investigated. One possibility is expression of specific alleles in the patient. Therefore, a 
search for sequence variants by direct sequencing was performed, described in Chapter 3; 
since we could not demonstrate the presence of a specific SNP linked to the disease in the 
candidate genes, we hypothesize that the observed changes in expression level are due to 
other sources, e.g. transcription factors or other regulatory molecules elicited in the 
disease process. Such factors nearly always affect multiple genes, so their presence can 
be inferred by looking for a concerted suite of effects (not always in the same direction or 
to the same extent) in pathways sharing the regulatory element. This type of analysis is 
covered by computational systems biology methods, e.g. pathway and network analysis.
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Identification of ‘signature’ networks that co-regulate the genes of interest often 
provide insights into the bigger picture of processes and development, by transitioning 
from examining single molecules to global states [113, 114]. Such states may include 
descriptions of the biologically relevant interactions between genes, proteins and 
compounds; the interactions are grouped into functional structures (described with 
specific ontologies) such as metabolic signaling, transcription factor interactions, 
regulatory networks and functional roles [124-128]. Collectively known as systems 
biology, analysis on this level is an important tool for discovery because a single 
phenotype may result from errors in any one of the many component elements of such 
pathways or networks [115]. 
Pathway analysis in previous sALS studies using human motor cortex samples 
emphasized the involvement of defense responses, cytoskeletal development, and 
mitochondrial and proteosomal dysfunction in ALS pathology [116]. More recently, 
Kudo et al. (2010) performed Gene Ontology analysis using DAVID [117, 118] on tissue 
microarrays from human postmortem spinal cord tissues from subjects with sALS that 
revealed associations between the biological processes corresponding to motor neurons 
and surrounding cells and protein modification/posphorylation, signaling, muscle 
contraction regulation, stress responses, immune responses and cell communications 
[119]. We would predict that immune responses, communication and signaling and stress 
responses would be propagated to the PBLs, the question being whether the responses are 
disease-specific or a general systems-alert.  
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Despite increasing evidence that peripheral blood can be a powerful source of 
biomarkers for neurological diseases, very few studies have attempted to use sALS blood 
samples. Results from studies of patients with multiple sclerosis [120], Alzheimer’s 
disease [121], Huntington’s disease [122], and a few with ALS [119, 123-125] have 
proved that the peripheral blood transcriptome is a reliable source for biomarker 
detection.  
More specifically for the current discussion, network analysis using weighted gene 
co-expression method on peripheral blood from ALS by Saris et al. (2009) found several 
significant pathways related to sALS, i.e. post-translational modification, infection 
mechanism, neurological disorder (Huntington), genetic disorder, skeletal and muscular 
disorder and inflammatory disease [123]. Zhang et al. (2011) show a strong association 
between aberrant activity of monocytes circulating in peripheral blood from patients with 
sALS and LPS (plasma endotoxin/lipopolysaccharide system) / TLR4 (toll-like receptor 
4) pathways, suggesting that activation of monocytes /macrophages via these signaling 
pathways would affect the disease progression [126]. 
However, early studies have used whole blood or peripheral blood mononuclear cells. 
There is an increased literature support for potential differences between the disease-
related signatures due to subpopulations of the cells, i. e. PBLs compared with monocytes 
and even subpopulations within the PBL grouping [127-129]. Therefore, it was suggested 
that, in order to detect disease-specific changes in transcription, it is necessary to profile 
purified leukocyte subsets [92, 127].  
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Taking this approach, an examination of microarray data from PBLs (a subpopulation 
of PBMCs) from subjects with sALS [75] showed alterations in the KEGG-designated 
ALS disease pathway, suggesting the propagation of gene expression changes first 
induced in brain and spinal cord tissue to cells in the circulating PBLs [116, 130]. We 
performed a pathway analysis using the genes identified as differentially expressed using 
the LO-BaFL pipeline (see Chapter 1), which differed from the TM4-based study 
described in [51] by a number of filters.  
Note: since TM4 genes have been already extensively discussed in the pathway 
context elsewhere [75], we do not replicate those comments here but only highlight the 
points most relevant to our own findings. 
4.2 Materials and Methods 
In order to identify the pathways and regulatory elements possibly associated with the 
genes in our list, we conducted an analysis using the MetaCore™ program, version 6.0. 
This is composed of a suite of tools for gene set enrichment analysis, multi-experiment 
comparison, interactome analysis and biological network identification [115]. The 
canonical pathways and network maps were obtained from the manually curated GeneGo 
database (GeneGo Inc., St. Joseph, MI) which incorporates, for human cells, protein-
protein, protein-DNA, and protein-compound interactions, as well as experimentally 
verified information on metabolic and signaling pathways [114]. Statistical tests (using 
hypergeometric distributions) assign to each pathway or network a corresponding p-
value, Z-score and G-score, to assess their change from baseline, depending on the degree 
of saturation of the modeled set with the objects from the initial gene list [131, 132]. 
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Networks with higher scores are considered more relevant to the phenotype, relative to 
the context presented in the specific data set. The p-value is corrected using the False 
Discovery Rate algorithm, which represents the probability that a given number of genes 
from the input list will match a certain number of gene nodes in the network [145, 146]. 
In this study, only pathways or networks with p < 0.01 were considered statistically 
significant. 
4.3 Results and Discussions 
As a first step, the entire set of sixty LO-BaFL differentially expressed genes 
(including those supported by qRT-PCR) with their corresponding intensities 
(Supplementary Material/ Data post filtering/ DE_genes_12_samples from Chapter 1) 
was uploaded in MetaCore for building the biological networks. The software returned 
twelve networks whose involvement met our criteria. The two most strongly supported 
pathways (G-score=42.8, p=1.44e-15) are involved in immune system signaling; the 
TWEAK gene (TNFSF12) via the TNF (tumor necrosis factor) receptor-associated 
factors 2 (TRAF2) or 5 (TRAF5). See Table 4.1 for Gene Ontology processes, and 
scores. To clarify the roles of these genes in the pathways, a GeneGo map of the network 
with the highlighted pathways is given in Figure 4.1. Other networks in which these 
genes participate are shown in Appendix A, Figure A1.  
The TWEAK (TNFSF12/ Apo-3L) gene codes for a type II transmembrane protein, 
and is a member of the TNF superfamily. The gene is involved in immune regulation, 
induced cell death, and hence inflammation [147-151]. Although it is expressed in 
various tissues, the highest levels of expression have been found in brain tissue skeletal 
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muscle, heart muscle and immune system cells [133]. It has been shown that the TWEAK 
signaling pathway has roles in apoptosis, proliferation, migration, angiogenesis, and 
inflammation [134].  
Several genes (ACTG1, DIA1, IRS2, JUNB) from our list participate in signaling 
pathways, alone or in combination. A myriad of complex processes can be invoked; we 
provide some examples that we consider most likely to be relevant to ALS below. 
ACTG1 participates in cytoskeleton remodeling by RhoGTPAse regulation of the actin 
cytoskeleton (Figure 4.2 (a)); in combination with DIA1 it is a component in immune 
responses via CCR3 signaling in the eosinophil pathway (Figure 4.2 (b)); in combination 
with IRS2, it has been shown to interact with alpha-6/beta-4 integrins in carcinoma 
progression (Figure 4.2 (c)) and it contributes to the regulation by growth factors of 
transport macropinocytosis (Figure 4.2 (d)). JUNB and IRS2 are part of developmental 
growth hormone signaling pathways, working through the PI3K/AKT and MAPK 
cascades (Figure 4.2 (e)).  
Our results are in good agreement with the work of Lederer et al. (2007), which 
showed the involvement of similar biological processes based on candidate genes derived 
from motor cortex samples from patients with sALS. The concurrence of gene expression 
results from PBLs to those of presumably more directly involved tissues is also suggested 
by the studies of Mougeot et al. (2011), perhaps not surprising where sensitive signaling 
cascades are involved. It does suggest that the microarray assay of PBLs, or derivative 
qPCR assays, are quite sensitive to the system-wide changes and that further cell sorting 
is not required. 
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Examination of the cross-section of functional networks (Table 4.1) by co-expression 
networks (Figure A1) shows the ribosomal proteins RPS10, RPS15A which are involved 
in translational regulation, but on further inspection, in Figure A1 (ii), these genes are in a 
set (RPS10, RPS25, RPS15A, RPL21), that, with the solute carrier transporter, SLC25A3, 
are part of an immune-response network, with the HLA-A, HLA-B, HLA-C proteins. 
Using a wider lens, members of the LO-BaFL gene set PABC1, PTMA, SFRS3, DIA1, 
LAMR1, FTH1, B2M, SLC25A3, CCDC6, OAZ1 also interact to regulate immune 
responses, and other types of cellular responses including apoptosis, which is discussed 
below. Some of their known interactions are with integrin-type proteins having roles in 
cell adhesion and cell-surface mediated signaling, and specifically with Myosin II and 
similar smooth muscle-specific genes whose degeneration is characteristic of ALS. That 
is, the genes converge in pathways that play important roles in sALS pathology. 
Some genes balance cell processes, especially ubiquitin. Ubiquitin helps up-regulate 
the subset of genes including PTMA, JUNB, SCP1, and OAZ1, seen in network 5 (Figure 
2A (iv)), and IRS2, JUNB seen in network 9 (see Table 4.1; graphics are not shown), 
whose functions include essential metabolic processes and cellular development. But 
upon interaction with PABPC1 and JUNB, ubiquitin leads to apoptosis, seen in network 
10 (Table 4.1). Aberrant forms of the ubiquitin protein and the resultant apoptosis are 
present in patients with neurodegenerative diseases, e.g. Alzheimer’s disease or Down’s 
syndrome [135]. Although this effect is well documented in motor neurons it is not 
reported for circulating cells, however the indication that it is induced is reinforced by the 
upregulation of IRS2, SPON2, and DIA1 shown in network 8 (see Table 4.1). 
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Figure 4.1 (upper) GenoGo map of networks with known interactions (highlighted lines). 
Red circles denote the genes from input list; (lower) Symbol legend (selections from 
MetaCore full legend). 
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(a) 
Figure 4.2. MetaCore analysis of signaling pathways in PBLs from sALS samples. 
Symbols are explained in the Figure 4.1 key. (a) cytoskeleton remodeling regulation of 
actin cytoskeleton by RhoGTPase; (b) immune responses via CCR3 signaling in 
eosinophils; (c) role of alpha-6/beta-4 integrins in carcinoma progression; (d) transport 
macropinocytosis regulation by growth factors; (e) development growth hormone 
signaling, via PI3K/AKT and MAPK cascades. Numbers in the red bars refer to the 
experiment in which the target was quantified. The letter for the mechanism involved is 
written inside the colored hexagon annotating the interaction arrow, abbreviations 
indicate the following: CF = complex formation; Cm = covalent modification; Tr = 
transcription regulation; B = binding; +P = phosphorylation; -P = dephosphorylation; Z = 
catalysis; Tn = transport; CS = complex subunit; GR = group relation. 
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(b) 
Figure 4.2 (continued). 
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(c) 
Figure 4.2 (continued). 
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(d) 
Figure 4.2 (continued). 
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(e) 
Figure 4.2 (continued). 
The last two networks in Table 4.1, involving JUNB and/ or OAZ1 are predicted to 
play roles in general cell responses to chemical stimulus and subsequent transcriptional 
regulation. 
 
78 
 
Regulation of cell processes over time is the product of many partially independent 
networks, from epigenetic marks to RNA polymerases whose activity is regulated by 
transcription factors to splicing, translation and protein modification. We next looked for 
evidence that specific sets of transcription factors (TFs, which are DNA binding proteins 
that regulate the transcription of their target genes by binding in the promoter region) 
were involved in the altered expression of the DE genes. Transcription factors are often 
expressed in very small amounts and any changes in their concentration are difficult to 
quantify, so TF networks are usually inferred based on enrichment of their binding sites, 
relative to randomly selected genes, in the DE genes [136]. The MetaCore software 
prioritizes the most statistically significant transcription factor networks, providing 
visualization with GeneGo maps, such as those shown in Figure 4.3. The prediction of 
activation versus deactivation is indicated by the arrow direction. For our set of genes, 29 
significant networks are predicted; of these 9 have been selected for discussion, based on 
their statistical importance (by p-value, Z-score and G-score): the scores and GO process 
annotations are given in Table 4.2. Only network 8 includes a known regulatory pathway 
(see Figure 4.3 (a)), discussed in detail after the individual TFs have been described. 
Only seven TFs (SP1, SP1/SP3, c-Myc, p63, ESR2, SREPB1 and STAT3) have the 
most significant influence patterns on our DE genes set, combining both activation and 
inhibition.  These are discussed in the following paragraphs. 
SP1 (specificity protein 1) causes cells to respond to various physiological or 
pathological stimuli. It is both an activator and repressor, affecting the transcription of 
many genes involved in cell growth, immune responses, and apoptosis [137]. When the 
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SP1/SP3 complex is dissected the proteins have been shown to carry a wide range of 
post-translational modifications, including phosphorylation, glycosylation, and 
proteolytic cleavage [138]. Previous studies have shown an association of SP1 regulated 
genes with neurodegenerative diseases, including Alzheimer’s [139] and Prion diseases 
[140]. SP1 positively regulates S100A6 (Calcyclin), IRS2, SLC25A3 and UBB as 
indicated in networks 1, and 5-8 (Figure 4.3 (a-b, f-h)). The mode of regulation for 
RPS10, OAZ1, PABC1, LAMR1, SCP1, and PSMA is unknown and likely depends on 
what other TFs are present.  SP1 is known to interact with the TFs E2F3 (network 1, 
Figure 4.3 (b)) and FB1-1 (network 5, Figure 4.3 (f)), which in turn are connected with 
JUNB through an unknown mode of action. SP1 activates the TF p63 that in turn inhibits 
JUNB and activates B2M (network 6, Figure 4.3 (g)). Through the p63 interaction it 
affects STAT3 (network 6, Figure 4.3 (g)) and HNF3 (network 9, Figure 4.3 (i)), the 
latter being responsible for JUNB upregulation; SP1 activates SLC 25A3, leading to a c-
Myc connection, that may also by modulated by several genes whose mechanism of 
interaction is currently unknown, including PABC1, RPS10, OAZ1, PSMA1 (network 8, 
Figure 4.3 (a)). SP1 is inhibited by RIPK1 kinase following positive regulation initiated 
by the TWEAK (TNFSF12) and TNFRSF12A receptors (Figure 4.3 (b, f-h)).  
The SP1/SP3 complex, shown in network 7 (Figure 4.3 (h)), has a more restricted set 
of functions than SP1 alone. It positively regulates UBB, SLC25A3, S100A6 and IRS2, 
while its regulation of PSMA1, OAZ1, SCP1, PABC1, RPS10 is more nuanced. The 
complex connects indirectly to the JUNB pathway through inhibition of the activated 
HMGA2 binding protein. 
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(a) 
Figure 4.3 GeneGo maps of transcription factors interaction networks (corresponding 
numbers are found in Table 4.2). Some symbols are explained in the Figure 4.1 key. (a) 
network 8; (b) network 1; (c) network 2; (d) network 3; (e) network 4; (f) network 5; (g) 
network 6; (h) network 7; (i) network 9. (j) Symbol legend from MetaCore. 
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           (b) 
                    (c) 
Figure 4.3 (continued) 
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                                     (d) 
                                           (e) 
Figure 4.3 (continued) 
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                                                                                     (f) 
    (g) 
  Figure 4.3 (continued). 
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                                                (h) 
                              (i) 
Figure 4.3 (continued). 
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(j) 
Figure 4.3 (continued) 
Appearing in four of the nine TFs networks, c-Myc or the c-Myc proto-oncogene, is 
known for its wide range of functions as transcription factor and particularly for its 
importance in various tumors, leukemias and lymphomas [141-143]. It is known to 
activate RPS15A and PTMA1, shown in networks 1-4 (Figure 4.3 (b-e)), but it inhibits 
TGOLN2. Its mode(s) of influence on PABC1, SLC25A3, RPS10, RPS25, OAZ1, PSMA1, 
JUNB, S100A6, ACTG1, SFRS3 is not currently known. c-Myc itself is activated by small 
GTPase Rac1, a member of RAS superfamily, following positive regulation from 
     
88 
 
TWEAK (TNFSF12) via the FN14 receptor. Transcription factors are themselves 
regulated by transcription factors, and c-Myc transcription is regulated by SP1 (network 
1), discussed above, HNF1-alpha and JUNB (network 2, Figure 4.3 (c)), STAT3 via 
JUNB (network 3, Figure 4.3 (d)) and ZNF206 (network 4, Figure 4.3 (e)). 
The p63 gene encodes a member of p53 family of transcription factors; it has known 
roles in development and the maintenance of stratified epithelial tissues [144].  As 
described above and shown in network 6 (Figure 4.3 (g)), p63 interacts directly with the 
TFs SP1 and STAT3 and regulates two of the DE genes, activating B2M and inhibiting 
JUNB. Similar to the TFs SP1 and c-Myc, p63 is activated through the pathway 
connecting the surface receptor TWEAK FN14 Rac1 STAT3 p63.  
STAT3 is one member of the large STAT family, that play key roles in many cellular 
processes, i.e. cell growth and apoptosis [145]. As seen in network 6, STAT3 activates 
JUNB and p63, and is induced by the small GTPase Rac1. 
The final two TFs, ESR2 (estrogen receptor 2) and SREPB1 (sterol regulatory 
element binding TF1) are part of a large network with complex regulatory interactions. 
Shown in network 8, Figure 4.3 (a)), the pathways also are modulated by SP1 and JUNB. 
The highlighted interactions show the positive regulation leading from 
Ubiquitin ESR2 SP1 SREBP1 precursor, but Ubiquitin itself is activated by 
interactions that start with the TWEAK (TNFSF12) ligand receptor. This highly 
connected network is the reason that such high-level GO processes are involved, i.e. cell 
maintenance and cell death. 
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4.4 Conclusions 
From a set of 60 differentially expressed genes, assayed from circulating white blood 
cells and selected using the LO-BaFL pipeline we used several forms of pathway analysis 
to see whether they are more likely connected to specific sALS pathology or to general 
disease responses. We input the entire list to derive the meaningful biological interactions 
and transcription factors networks from GeneGo maps of MetaCore. 12 statistically 
significant networks involving several of the selected genes were obtained; the most 
highly ranked was TWEAK (TNFSF12) via TNF receptor-associated factors 2 (TRAF2) 
or 5 (TRAF5). Of the constituent genes, ACTG1, IRS2, DIA1 and JUNB in a variety of 
associations promote processes such as cytoskeleton remodeling, regulation of the actin 
cytoskeleton by RhoGTPase, immune responses via CCR3 signaling in eosinophils, the 
role of alpha-6/beta-4 integrins in carcinoma progression, transport macropinocytosis 
regulation by growth factors, development growth hormone signaling, via PI3K/AKT and 
MAPK cascades, with many other roles in apoptosis, proliferation, migration, 
angiogenesis, and inflammation [134]. These are in good agreement with previous 
reports [116, 119, 123].  
As would be expected in a disease in which cell death occurs, many of the genes are 
part of immune response pathways (HLA-type), including RPS10, RPS15A, RPS25, 
RPL21, LAMR1 and SLC25A3, other genes participate in regulation of the immune 
response or responses to other stimuli including PABC1, PTMA, SFRS3, DIA1, LAMR1, 
FTH1, B2M, SLC25A3, CCDC6, OAZ1. Responses more specific to a disease involving 
muscle-neuron interactions were seen for integrin-type proteins with roles in cell 
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adhesion and cell-surface mediated signaling, and with Myosin II and myosin smooth 
muscle specific genes characteristic of ALS.  
Programmed cell death and cellular responses to the products of those events are 
prominent through networks that include ubiquitin, UBB. Examples of affected genes 
include PTMA, JUNB, SCP1, OAZ1, IRS2 or PABC1, while IRS2, SPON2, DIA1 are 
nodes in one network that regulates apoptosis. Other networks including JUNB and / or 
OAZ1 are predicted to play roles in cell responses to chemical stimulus. Although we do 
not show here the direct affect of these genes on Ubiquitin/Proteasome System that has 
been proved to perturb the ALS pathway [92], the presence of Ubiquitin in several 
significant interaction networks might suggest a similar trend. 
MetaCore also derived 29 statistically significant transcription factors networks, for 
which we summarized the 9 most significant. SP1, SP1/SP3, c-Myc, p63, STAT3, ESR2 
and SREPB1 were identified although not all of the interactions are currently defined. For 
instance, S100A6, IRS2, UBB and SLC25A3 are activated by SP1 or the SP1/SP3 
complex, but the way they regulate RPS10, PABC1, LAMR1, SCP1, OAZ1, PSMA is not 
known. c-Myc activates RPS15A and PTMA, while it inhibits TGOLN2 and the mode of 
action is not known for  PABC1, SLC25A3, RPS10, OAZ1, PSMA1, JUNB, S100A6, 
RPS25, ACTG1 and SFRS3. JUNB, in direct connection with STAT3 and p63, is 
activated by the first and inhibited by the latter, which in turn stimulates B2M activity. 
PTMA activity is shown to be stimulated by ESR2, while IRS2 is inactivated by SREPB1.  
Because the targeted cells were of several types, an effect in one cell type may mask an 
opposing effect in another cell type, particularly when complexes of TFs have different 
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effects.  For instance, p63 in Figure 4.3 (g) is activated by two other TFs: SP1 and 
STAT3, as a result of which B2M becomes activated while JUNB is repressed. 
It is interesting that a large subset of the DE genes in our list (ACTG1, IRS2, DIA1, 
JUNB, PABC1, PTMA, SFRS3, LAMR1, FTH1, B2M, SLC25A3, CCDC6, OAZ1, UBB, 
RPS10, RPS15A, RPS25, RPL21, PSMA1, S100A6, TGOLN2, SFRS3, SCP1) are 
regulatory and while many are engaged in normal cell processes that are perhaps ramped 
up to accommodate a higher than normal cell turnover, the immune response signature 
and apoptosis and responses to chemical stimulus are likely more specific to sALS and 
are good candidates for a simplified blood-based biomarker signature for its presence 
than have been yielded by previous studies. The mechanism of action and their exact role 
in sALS pathology is still to be determined by future work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
92 
 
SUMMARY 
 
 
Amyotrophic Lateral Sclerosis is a heterogeneous, complex disease whose etiology is 
poorly understood, despite many studies performed over many sample types, from 
biopsies to biofluids, and DNA, RNA and proteins. The goal of the present study was to 
find diagnostic markers that will help determine who has ALS, hopefully as early as 
possible and in a readily obtainable medium, in this case blood, which is drawn during 
most routine physicals.  This has immediate benefits in the clinic, since with a 18 month-
5 year life expectancy even the gain of 2-3 months from Riluzol is significant. We were 
looking for markers that are clearly present in all patients of a particular group and 
clearly distinct from individuals in the contrast group, whether as present/absent 
expression of genes, or expression levels that are completely distinct. 
The approach taken in the first stage of this research was to revise the array design for 
a set of microarray experiments in order to remove design errors and compare the 
subsequent predictions of differential expression to the standard method. As a control, an 
independent experiment performed on the same platform for which independent assays 
had been performed to test the microarray predictions was analyzed, despite not being 
focused on the disease phenotype of interest (CAD versus sALS). The novel pipeline, 
LO-BaFL, was developed to correct for errors that arise in microarray design, i.e. cross-
hybridization, loss of binding site, miss-assignment of particular probes. Because of its 
strict filtering, LO-BaFL improves the power and discrimination of identifying the 
differentially expressed genes but also it eliminates genes that are not problematic in 
specific populations.  
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Comparison of the responses from a similar set of Normal samples in an independent 
study using the same Agilent platform revealed a good correlation (R=0.81) between 
Healthy Controls in sALS and CAD studies, giving us confidence in the disease 
responses as well. 
LO-BaFL pipeline, and SAM and TM4 as comparative methods, were used to cleanse 
data and analyze microarray data from sALS study. LO-BaFL revealed a subset of 87 DE 
genes, versus 209 of SAM and 264 of TM4. Of particular note was that by combining 
TM4, which predicts a TARDBP expression change, with LO-BaFL, which indicates that 
4 genes all contribute signal to the probe mapped to TARDBP, it became clear that 
several genes had to be tested in the follow-up assay, including ILKAP.  
After comparing the three lists of DE genes identified by LO-BaFL, SAM and TM4, 
we selected the top genes for validation with qRT-PCR assay, an independent method. 
Such validation is recommended as a follow-up for microarray predictions. The selected 
genes are described in details in Chapter 2. 
The biomolecular assays have been performed on RNA - derived PBLs samples from 
subjects with sALS. Testing of 12 genes with qRT-PCR, using the samples that passed 
the quality assessment (RIN > 5.5) confirmed the microarray observations and most of 
our computational predictions when applying LO-BaFL and comparative methods for 
microarray analysis: ACTG1, SKIV2L2, C12orf35, B2M, DYNLT1, ILKAP, TARDBP 
were found to have higher expression ratio in patients with sALS vs. Healthy Controls. 
With respect to the genes listed, the corresponding expression ratio values are: 48.5; 37.3; 
22.4; 18.2; 17.4; 8.8; 5.6. This confirms the results of previous and more recent studies 
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[8, 12, 75, 92], with additional new candidate biomarkers in the genes ACTG1, B2M, 
ILKAP. Also importantly, qRT-PCR results confirmed TARDBP is among the DE genes 
for sALS. However, the results show less differential expression than the microarray 
predicted. This is due to increased expression of two genes that cross-hybridize 
(TARDBP and ILKAP) measured by the same Agilent probe.  
Following up on selected DE transcripts, we searched for the presence of sequence 
variants, e.g. SNPs, by performing Sanger sequencing assays, as described in Chapter 3. 
Direct sequencing was performed to screen for possible mutations in selected exons 
of DE genes determined by the LO-BaFL pipeline, for the five Healthy Controls and five 
sALS samples that passed quality control step. No sequence variant that consistently 
segregated with the sALS samples was found. In 9 out of 10 samples we identified a 
novel mutation in exon 3 of the ACTG1 gene, c.350 C-to-T, as follows: 
       TCTGGCACCACACCTTCTACAA[C/T]GAGCTGCGCGTGGCCCCGGAGGAGCAC 
However, since we found this variant in what are labeled ‘Healthy Controls’, it does not 
correlate with sALS.  
For the other DE genes tested, since the exons do show differential expression, but no 
sequence variant was found, we assume that changes could have other causes: more 
distant structural changes or regulatory changes due to presence of transcription factors or 
other modulators. This is one type of pathway analysis we performed, described in 
Chapter 4. 
We input the entire LO-BaFL DE genes list to derive the meaningful biological 
interactions and transcription factors networks from GeneGo maps of MetaCore. Twelve 
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statistically significant networks involving several of the selected genes were obtained; 
the most highly ranked was TWEAK (TNFSF12) via TNF receptor-associated factors 2 
(TRAF2) or 5 (TRAF5), with roles in apoptosis, proliferation, angiogenesis and 
inflammation. Of the constituent genes, ACTG1, IRS2, DIA1 and JUNB in a variety of 
associations promote processes such as cytoskeleton remodeling, immune responses, 
playing roles in carcinoma progression, transport macropinocytosis regulation by growth 
factors, development growth hormone signaling, via PI3K/AKT and MAPK cascades, 
with many other roles in apoptosis, proliferation, migration, angiogenesis, and 
inflammation [134]. These are in good agreement with previous reports [116, 119, 123].  
Many of the genes are part of immune response pathways (HLA-type), including 
RPS10, RPS15A, RPS25, RPL21, LAMR1 and SLC25A3, other genes participate in 
regulation of the immune response or responses to other stimuli including PABC1, 
PTMA, SFRS3, DIA1, LAMR1, FTH1, B2M, SLC25A3, CCDC6, OAZ1. Responses more 
specific to a disease involving muscle-neuron interactions were seen for integrin-type 
proteins with roles in cell adhesion and cell-surface mediated signaling, and with Myosin 
II and myosin smooth muscle specific genes characteristic of ALS.  
MetaCore also derived 29 statistically significant transcription factor networks, for 
which we summarized the 9 most significant. SP1, SP1/SP3, c-Myc, p63, STAT3, ESR2 
and SREPB1 were identified although not all of the interactions are currently defined. A 
large selection of genes from our input list (ACTG1, IRS2, DIA1, JUNB, PABC1, PTMA, 
SFRS3, LAMR1, FTH1, B2M, SLC25A3, CCDC6, OAZ1, UBB, RPS10, RPS15A, RPS25, 
RPL21, PSMA1, S100A6, TGOLN2, SFRS3, SCP1), regulated by these transcription 
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factors, are regulatory, and while many are engaged in normal cell processes that are 
perhaps ramped up to accommodate a higher than normal cell turnover, the immune 
response signature and apoptosis and responses to chemical stimulus are likely more 
specific to sALS and are good candidates for a simplified blood-based biomarker.  
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APPENDIX A: ADDITIONAL NETWORK INTERACTIONS 
 
 
  
(i) 
 
Figure A1. Other relevant networks (from Table 4.1) for our selection of genes. (i) 
network 2, (ii) network 3;(iii) network 4; (iv) network 5; (v) network 6. 
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(ii) 
 
Figure A1 (continued). 
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  (iii) 
    (iv) 
Figure A1 (continued). 
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(v) 
 
Figure A1 (continued). 
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